STATISTICAL COMPENDIUM: MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT IN 2004 WASHINGTON

LIST OF TABLES

OVERVIEW OF STUDY POPULATION

TABLE 1. OVERVIEW OF BENEFICIARY SELECTION CRITERIA FOR STUDY POPULATION

FOR ALL MEDICAID BENEFICIARIES

- TABLE 2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES. BY BASIS OF ELIGIBILITY
- TABLE 3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC
- TABLE 4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE 5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC
- TABLE 6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE 7. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

FOR ALL NONDUAL BENEFICIARIES

TABLE ND.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES. BY BASIS OF ELIGIBILITY

TABLE ND.3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE ND.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH. BY BENEFICIARY CHARACTERISTIC

TABLE ND.5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC

TABLE ND.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE ND.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

TABLE ND.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC

TABLE ND.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE ND.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS. BY TOP 10 DRUG GROUP

TABLE ND.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS, BY BENEFICIARY CHARACTERISTIC

TABLE ND.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS PER BENEFIT MONTH. BY BENEFICIARY CHARACTERISTIC

TABLE ND.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG NONDUALS

FOR DUAL ELIGIBLE BENEFICIARIES

- TABLE D.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES. BY BASIS OF ELIGIBILITY
- TABLE D.3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY. BY BENEFICIARY CHARACTERISTIC
- TABLE D.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE D.5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC
- TABLE D.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE D.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP
- TABLE D.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC
- TABLE D.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE D.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY TOP 10 DRUG GROUP
- TABLE D.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS, BY BENEFICIARY CHARACTERISTIC
- TABLE D.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE D.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG DUALS

SUPPLEMENTAL TABLES

SUPPLEMENTAL TABLE 1. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES

SUPPLEMENTAL TABLE 1A. MEDICAID PHARMACY REIMBURSEMENT FOR DISABLED DUAL ELIGIBLE BENEFICIARIES UNDER AGE 65

SUPPLEMENTAL TABLE 1B. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 AND OLDER

SUPPLEMENTAL TABLE 1C. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 TO 74

SUPPLEMENTAL TABLE 1D. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 75 TO 84

SUPPLEMENTAL TABLE 1E. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 85 AND OLDER

APPENDIX TABLES

APPENDIX TABLE A.1. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, NONDUAL BENEFICIARIES

APPENDIX TABLE A.2. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, NONDUAL BENEFICIARIES

APPENDIX TABLE A.3. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, DUAL ELIGIBLE BENEFICIARIES

APPENDIX TABLE A.4. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, DUAL ELIGIBLE BENEFICIARIES

TABLE D.2

CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY^{a, b}

DUAL ELIGIBLE BENEFICIARIES, WASHINGTON, 2004

| | | | Number of Ben | eficiaries | | | | N | lumber of Bene | efit Months | | |
|----------------------------------------|---------|--------|---------------|------------|----------|---------|-----------|---------|----------------|-------------|----------|---------|
| Beneficiary | | | | | | Other/ | | | | | | Other/ |
| Characteristics | All | Aged | Disabled | Adults | Children | Unknown | All | Aged | Disabled | Adults | Children | Unknown |
| All | 101,583 | 57,080 | 43,706 | 779 | 18 | 0 | 1,079,506 | 594,141 | 479,450 | 5,730 | 185 | 0 |
| Age | | | | | | | | | | | | |
| 5 and younger | 9 | 0 | 7 | 0 | 2 | 0 | 100 | 0 | 76 | 0 | 24 | 0 |
| 6-14 | 20 | 0 | 14 | 0 | 6 | 0 | 209 | 0 | 152 | 0 | 57 | 0 |
| 15-20 | 174 | 0 | 161 | 4 | 9 | 0 | 1,927 | 0 | 1,806 | 28 | 93 | 0 |
| 21-44 | 19,596 | 3 | 18,999 | 593 | 1 | 0 | 213,906 | 25 | 209,428 | 4,442 | 11 | 0 |
| 45-64 | 24,566 | 24 | 24,375 | 167 | 0 | 0 | 268,227 | 195 | 266,895 | 1,137 | 0 | 0 |
| 65-74 | 21,283 | 21,121 | 148 | 14 | 0 | 0 | 229,970 | 228,782 | 1,075 | 113 | 0 | 0 |
| 75-84 | 20,283 | 20,280 | 2 | 1 | 0 | 0 | 211,858 | 211,830 | 18 | 10 | 0 | 0 |
| 85 and older | 15,652 | 15,652 | 0 | 0 | 0 | 0 | 153,309 | 153,309 | 0 | 0 | 0 | 0 |
| Unknown | 0 | 0 | 0 | 0 | 0 | 0 | | 0 | 0 | 0 | 0 | 0 |
| Gender | | | | | | | | | | | | |
| Female | 63,373 | 40,536 | 22,308 | 517 | 12 | 0 | 674,881 | 424,473 | 246,370 | 3,915 | 123 | 0 |
| Male | 38,210 | 16,544 | 21,398 | 262 | 6 | 0 | 0 404,625 | 169,668 | 233,080 | 1,815 | 62 | 0 |
| Unknown | 0 | 0 | 0 | 0 | 0 | 0 | | 0 | 0 | 0 | 0 | 0 |
| Race | | | | | | | | | | | | |
| White | 77,625 | 41,192 | 35,901 | 520 | 12 | 0 | 821,164 | 421,289 | 395,900 | 3,850 | 125 | 0 |
| African American | 4,772 | 1,780 | 2,936 | 55 | 1 | 0 | 0 50,806 | 19,063 | 31,306 | 425 | 12 | 0 |
| Other/unknown | 19,186 | 14,108 | 4,869 | 204 | 5 | 0 | 207,536 | 153,789 | 52,244 | 1,455 | 48 | 0 |
| Use of Nursing Facilities ^c | | | | | | | | | | | | |
| Entire year | 8,532 | 7,694 | 838 | 0 | 0 | 0 | 87,225 | 78,013 | 9,212 | 0 | 0 | 0 |
| Part year | 7,370 | 6,398 | 971 | 1 | 0 | 0 | 69,047 | 58,986 | 10,049 | 12 | 0 | 0 |
| None | 85,681 | 42,988 | 41,897 | 778 | 18 | 0 | 923,234 | 457,142 | 460,189 | 5,718 | 185 | 0 |
| Maintenance Assistance Status | | | | | | | | | | | | |
| Cash | 51,079 | 23,417 | 27,490 | 170 | 2 | 0 | 566,336 | 263,834 | 301,347 | 1,136 | 19 | 0 |
| Medically needy | 2,250 | 834 | 1,416 | 0 | 0 | 0 | 23,469 | 8,472 | 14,997 | 0 | 0 | 0 |
| Poverty-related | 3,326 | 1,424 | 1,757 | 138 | 7 | 0 | 28,477 | 11,069 | 16,150 | 1,199 | 59 | 0 |
| Other/unknown | 44,928 | 31,405 | 13,043 | 471 | 9 | 0 | 461,224 | 310,766 | 146,956 | 3,395 | 107 | 0 |
| Dual Medicare Status ^d | | | | | | | | | | | | |
| Full dual, all year | 96,613 | 54,709 | 41,158 | 728 | 18 | 0 | 1,028,762 | 570,819 | 452,565 | 5,193 | 185 | 0 |
| Full dual, part year | 4,970 | 2,371 | 2,548 | 51 | 0 | 0 | 50,744 | 23,322 | 26,885 | 537 | 0 | 0 |
| Managed Care (MC) Status | | | | | | | | | | | | |
| Fee-for-service (FFS) all year | 101,044 | 57,015 | 43,426 | 588 | 15 | 0 | 1,076,725 | 593,770 | 477,814 | 4,978 | 163 | 0 |
| FFS part year, with Rx claims | 456 | 47 | 246 | 160 | 3 | 0 | 2,445 | 283 | 1,473 | 667 | 22 | 0 |
| FFS part year, no Rx claims | 83 | 18 | 34 | 31 | 0 | 0 | 336 | 88 | 163 | 85 | 0 | 0 |

- a. Table D.2 includes the beneficiaries represented by Cell G of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.
- c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.
- d. The "Full dual, all year" group contains beneficiaries who had Medicare as well as Medicaid fee-for-service pharmacy benefits during all months of Medicaid enrollment in 2004. The "Full dual, part year" group contains beneficiaries who had such benefits for some, but not all, months of their enrollment. Refer to footnote g of Table 1 for more information about how we determined dual eligibility status.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; Rx = pharmacy benefit.

TABLE D.3

ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC^{a, b}

DUAL ELIGIBLE BENEFICIARIES, WASHINGTON, 2004

| Beneficiary | Percentage with at | | | | Mean \$, All | Rx \$ as a Percentage of All Medicaid | Number of |
|-----------------------------------|---------------------|------|------------|-----------|------------------|---------------------------------------|---------------|
| Characteristics | Least One Rx Mean I | | Mean Rx \$ | \$ per Rx | Medicaid FFS \$c | FFS \$ ^d | Beneficiaries |
| All | 89.5 % | 51.3 | \$2,896 | \$56 | \$12,157 | 23.8 % | 101,583 |
| Age | | | | | | | |
| 5 and younger | 100.0 | 42.9 | 8,751 | 204 | 112,324 | 7.8 | 9 |
| 6-14 | 100.0 | 39.8 | 8,764 | 220 | 22,654 | 38.7 | 20 |
| 15-20 | 78.2 | 18.2 | 2,191 | 120 | 10,476 | 20.9 | 174 |
| 21-44 | 84.6 | 35.9 | 3,081 | 86 | 8,799 | 35.0 | 19,596 |
| 45-64 | 89.4 | 58.6 | 3,945 | 67 | 11,674 | 33.8 | 24,566 |
| 65-74 | 88.4 | 53.0 | 2,556 | 48 | 9,065 | 28.2 | 21,283 |
| 75-84 | 91.7 | 55.6 | 2,454 | 44 | 13,798 | 17.8 | 20,283 |
| 85 and older | 94.3 | 51.7 | 2,053 | 40 | 19,147 | 10.7 | 15,652 |
| Unknown | 0.0 | 0.0 | 0 | 0 | 0 | 0.0 | 0 |
| Basis of Eligibility ^e | | | | | | | |
| Aged | 91.2 | 53.6 | 2,384 | 45 | 13,511 | 17.6 | 57,080 |
| Disabled | 87.5 | 48.9 | 3,597 | 74 | 10,544 | 34.1 | 43,706 |
| Adults | 68.2 | 16.0 | 1,114 | 70 | 3,110 | 35.8 | 779 |
| Children | 88.9 | 28.7 | 3,263 | 114 | 26,532 | 12.3 | 18 |
| Unknown | 0.0 | 0.0 | 0 | 0 | 0 | 0.0 | 0 |
| Gender | | | | | | | |
| Female | 92.1 | 57.1 | 2,967 | 52 | 12,835 | 23.1 | 63,373 |
| Male | 85.0 | 41.8 | 2,780 | 67 | 11,034 | 25.2 | 38,210 |
| Unknown | 0.0 | 0.0 | 0 | 0 | 0 | 0.0 | 0 |
| Race | | | | | | | |
| White | 89.8 | 53.8 | 3,094 | 58 | 13,261 | 23.3 | 77,625 |
| African American | 88.0 | 46.9 | 2,711 | 58 | 10,261 | 26.4 | 4,772 |
| Other/unknown | 88.6 | 42.5 | 2,143 | 50 | 8,164 | 26.2 | 19,186 |
| Use of Nursing | | | | | | | |
| Facilities ^f | | | | | | | |
| Entire year | 97.7 | 68.4 | 3,270 | 48 | 41,264 | 7.9 | 8,532 |
| Part year | 98.1 | 62.8 | 3,052 | 49 | 24,002 | 12.7 | 7,370 |
| None | 87.9 | 48.6 | 2,846 | 59 | 8,240 | 34.5 | 85,681 |
| Maintenance Assistance Status | | | | | | | |
| Cash | 89.1 | 45.1 | 2,718 | 60 | 5,784 | 47.0 | 51,079 |
| Medically needy | 94.5 | 53.2 | 3,986 | 75 | 9,270 | 43.0 | 2,250 |
| Poverty related | 47.5 | 13.4 | 818 | 61 | 2,065 | 39.6 | 3,326 |
| Other/unknown | 92.8 | 61.1 | 3,199 | 52 | 20,295 | 15.8 | 44,928 |

- a. Table D.3 includes beneficiaries represented by Cell G of Table 1.
- b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. In seven states (DE, IA, NE, NY, TX, UT, and WV) the expenditures in this column include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. As a result, the amounts shown in this column for all Medicaid fee-for-service expenditures are lower than they would otherwise be.
- d. In seven states (DE, IA, NE, NY, TX, UT, and WV) the Rx share of expenditures for all Medicaid services shown in this column is higher than it would be if all expenditures for these other services, including services provided in capitated managed care plans and long-term-care services, were included.
- e. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- f. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE D.4

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT *PER BENEFIT MONTH*, BY BENEFICIARY CHARACTERISTIC^{a, b}

DUAL ELIGIBLE BENEFICIARIES, WASHINGTON, 2004

| | | | | | N | umber of Rx, Pe | rcentage with: | | | _ | Numb | er |
|-------------------------------------------|-------------------|------------|--------------------------------------|--------|---------------------|----------------------------------|----------------------------|-----------------------------|-----------|-------------------------------------------------|---------------|--------------------------------|
| Beneficiary Characteristics | Mean Number of Rx | Mean Rx \$ | Rx \$ as a ercentage of All Medicaid | None | 0, but 1 or Less | More than 1, but 2 or Less | More than 2, but 5 or Less | More than 5, but 10 or Less | More than | Mean \$, All Medicaid FFS \$ ^d | Beneficiaries | Benefit Months 1,079,506 |
| All | 4.8 | \$273 | 23.8 % | 10.5 % | 14.9 % | 9.9 % | 28.2 % | 27.3 % | 9.2 % | \$1,144 | 101,583 | 1,079,506 |
| Age | | | | | | | | | | | | |
| 5 and younger | 3.9 | 788 | 7.8 | 0.0 | 11.1 | 33.3 | 0.0 | 55.6 | 0.0 | 10,109 | 9 | 100 |
| 6-14 | 3.8 | 839 | 38.7 | 0.0 | 10.0 | 40.0 | 30.0 | 20.0 | 0.0 | 2,168 | 20 | 209 |
| 15-20 | 1.6 | 198 | 20.9 | 21.8 | 39.7 | 11.5 | 23.0 | 3.4 | 0.6 | 946 | 174 | 1,927 |
| 21-44 | 3.3 | 282 | 35.0 | 15.4 | 26.2 | 12.7 | 25.0 | 15.9 | 4.8 | 806 | 19,596 | 213,906 |
| 45-64 | 5.4 | 361 | 33.8 | 10.6 | 13.2 | 8.8 | 26.2 | 28.3 | 12.9 | 1,069 | 24,566 | 268,227 |
| 65-74 | 4.9 | 237 | 28.2 | 11.6 | 13.9 | 9.4 | 28.4 | 27.1 | 9.6 | 839 | 21,283 | 229,970 |
| 75-84 | 5.3 | 235 | 17.8 | 8.3 | 11.0 | 8.9 | 29.5 | 32.3 | 9.9 | 1,321 | 20,283 | 211,858 |
| 85 and older | 5.3 | 210 | 10.7 | 5.7 | 9.8 | 9.6 | 33.3 | 34.2 | 7.4 | 1,955 | 15,652 | 153,309 |
| Unknown | 0.0 | 0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0 | 0 | 0 |
| Basis of Eligibility ^e | | | | | | | | | | | | |
| Aged | 5.2 | 229 | 17.6 | 8.8 | 11.7 | 9.3 | 30.2 | 30.9 | 9.1 | 1,298 | 57,080 | 594,141 |
| Disabled | 4.5 | 328 | 34.1 | 12.5 | 18.9 | 10.5 | 25.8 | 23.0 | 9.4 | 961 | 43,706 | 479,450 |
| Adults | 2.2 | 151 | 35.8 | 31.8 | 24.5 | 12.2 | 16.7 | 10.8 | 4.0 | 423 | 779 | 5,730 |
| Children | 2.8 | 318 | 12.3 | 11.1 | 11.1 | 27.8 | 33.3 | 16.7 | 0.0 | 2,582 | 18 | 185 |
| Unknown | 0.0 | 0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0 | 0 | 0 |
| Gender | | | | | | | | | | | | |
| Female | 5.4 | 279 | 23.1 | 7.9 | 12.4 | 9.3 | 28.7 | 30.8 | 11.0 | 1,205 | 63,373 | 674,881 |
| Male | 3.9 | 263 | 25.2 | 15.0 | 19.2 | 10.8 | 27.2 | 21.6 | 6.2 | 1,042 | 38,210 | 404,625 |
| Unknown | 0.0 | 0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0 | 0 | 0 |
| Race | | | | | | | | | | | | |
| White | 5.1 | 293 | 23.3 | 10.2 | 13.9 | 9.3 | 27.3 | 28.8 | 10.4 | 1,254 | 77,625 | 821,164 |
| African American | 4.4 | 255 | 26.4 | 12.0 | 19.0 | 10.0 | 27.3 | 23.8 | 7.9 | 964 | 4,772 | 50,806 |
| Other/unknown | 3.9 | 198 | 26.2 | 11.4 | 17.9 | 12.2 | 31.8 | 22.3 | 4.4 | 755 | 19,186 | 207,536 |
| use or nursing Facilities ^f | | | | | | | | | | | | |
| Entire year | 6.7 | 320 | 7.9 | 2.3 | 5.9 | 7.1 | 27.4 | 40.8 | 16.5 | 4,036 | 8,532 | 87,225 |
| Part year | 6.7 | 326 | 12.7 | 1.9 | 6.3 | 7.1 | 30.7 | 39.1 | 14.8 | 2,562 | 7,370 | 69,047 |
| None | 4.5 | 264 | 34.5 | 12.1 | 16.6 | 10.4 | 28.0 | 25.0 | 8.0 | 765 | 85,681 | 923,234 |
| Maintenance Assistance Status | | | | | | | | | | | | |
| Cash | 4.1 | 245 | 47.0 | 10.9 | 19.7 | 11.5 | 29.5 | 22.2 | 6.2 | 522 | 51,079 | 566,336 |
| Medically needy | 5.1 | 382 | 43.0 | 5.5 | 13.1 | 11.5 | 30.2 | 30.2 | 9.5 | 889 | 2,250 | 23,469 |
| Poverty related | 1.6 | 96 | 39.6 | 52.5 | 19.8 | 8.5 | 12.6 | 5.8 | 0.9 | 241 | 3,326 | 28,477 |
| Other/unknown | 5.9 | 312 | 15.8 | 7.2 | 9.2 | 8.0 | 27.7 | 34.7 | 13.2 | 1,977 | 44,928 | 461,224 |

Table D4

Dual Eligible Beneficiaries

- a. Table D.4 includes the beneficiaries represented by Cell G of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. In seven states (DE, IA, NE, NY, TX, UT, and WV) the expenditures in this column include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. As a result, the amounts shown in this column for all Medicaid fee-for-service expenditures are lower than they would otherwise be.
- d. In seven states (DE, IA, NE, NY, TX, UT, and WV) the Rx share of expenditures for all Medicaid services shown in this column is higher than it would be if all expenditures for these other services, including services provided in capitated managed care plans and long-term-care services, were included.
- e. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- f. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE D.5

AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC^{6, b, c}

DUAL ELIGIBLE BENEFICIARIES, WASHINGTON, 2004

| Beneficiary | | All Rx | | Patented Br | and-Name | Drugs | Off-Patent B | Brand-Name | Drugs | Gen | eric Drugs | |
|----------------------------------------|--------|--------|-----------|-------------|----------|-----------|--------------|------------|-----------|--------|------------|-----------|
| _ | Number | | | Number | | | Number | | | Number | | |
| Characteristics | of Rx | Rx\$ | \$ per Rx | of Rx | Rx\$ | \$ per Rx | of Rx | Rx\$ | \$ per Rx | of Rx | Rx\$ | \$ per Rx |
| All | 4.8 | \$273 | \$56 | 1.6 | \$198 | \$120 | 0.2 | \$17 | \$76 | 2.9 | \$57 | \$19 |
| Age | | | | | | | | | | | | |
| 5 and younger | 3.9 | 788 | 204 | 1.8 | 597 | 334 | 0.2 | 46 | 271 | 1.9 | 144 | 77 |
| 6-14 | 3.8 | 839 | 220 | 1.5 | 752 | 507 | 0.2 | 10 | 42 | 2.1 | 59 | 29 |
| 15-20 | 1.6 | 198 | 120 | 0.7 | 164 | 232 | 0.1 | 8 | 59 | 0.8 | 26 | 32 |
| 21-44 | 3.3 | 282 | 86 | 1.2 | 218 | 181 | 0.2 | 19 | 111 | 1.9 | 45 | 24 |
| 45-64 | 5.4 | 361 | 67 | 1.8 | 261 | 143 | 0.3 | 27 | 103 | 3.3 | 73 | 22 |
| 65-74 | 4.9 | 237 | 48 | 1.7 | 169 | 100 | 0.2 | 13 | 65 | 3.0 | 55 | 18 |
| 75-84 | 5.3 | 235 | 44 | 1.8 | 168 | 92 | 0.2 | 12 | 50 | 3.2 | 55 | 17 |
| 85 and older | 5.3 | 210 | 40 | 1.7 | 147 | 88 | 0.3 | 11 | 40 | 3.3 | 52 | 16 |
| Unknown | 0.0 | 0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0 |
| Basis of Eligibility ^d | | | | | | | | | | | | |
| Aged | 5.2 | 229 | 45 | 1.7 | 163 | 94 | 0.2 | 12 | 52 | 3.2 | 54 | 17 |
| Disabled | 4.5 | 328 | 74 | 1.6 | 243 | 156 | 0.2 | 24 | 106 | 2.7 | 61 | 23 |
| Adults | 2.2 | 151 | 70 | 0.7 | 104 | 156 | 0.1 | 17 | 131 | 1.4 | 31 | 22 |
| Children | 2.8 | 318 | 114 | 1.0 | 250 | 251 | 0.2 | 15 | 86 | 1.6 | 52 | 32 |
| Unknown | 0.0 | 0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0 |
| Gender | | | | | | | | | | | | |
| Female | 5.4 | 279 | 52 | 1.8 | 199 | 110 | 0.3 | 18 | 71 | 3.3 | 61 | 19 |
| Male | 3.9 | 263 | 67 | 1.4 | 197 | 142 | 0.2 | 16 | 87 | 2.4 | 50 | 21 |
| Unknown | 0.0 | 0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0 |
| Race | | | | | | | | | | | | |
| White | 5.1 | 293 | 58 | 1.7 | 212 | 123 | 0.2 | 19 | 78 | 3.1 | 61 | 20 |
| African American | 4.4 | 255 | 58 | 1.5 | 189 | 130 | 0.2 | 15 | 72 | 2.7 | 51 | 18 |
| Other/unknown | 3.9 | 198 | 50 | 1.4 | 146 | 103 | 0.1 | 10 | 65 | 2.3 | 42 | 18 |
| Use of Nursing Facilities ^e | | | | | | | | | | | | |
| Entire year | 6.7 | 320 | 48 | 2.2 | 225 | 102 | 0.4 | 23 | 51 | 4.0 | 71 | 18 |
| | 6.7 | 326 | 46 49 | 2.2 | 232 | 102 | 0.4 | 23 21 | 51 54 | 4.0 | 71 | 18 |
| Part year None | 4.5 | 264 | 49 59 | 1.6 | 193 | 124 | 0.4 | 16 | 84 | 2.8 | 73 54 | 20 |
| Maintenance Assistance | | | | | | | | | | | | |
| Status | | | | | | | | | | | | |
| Cash | 4.1 | 245 | 60 | 1.4 | 181 | 126 | 0.2 | 14 | 88 | 2.5 | 49 | 20 |
| Medically needy | 5.1 | 382 | 75 | 1.8 | 290 | 158 | 0.3 | 29 | 113 | 3.0 | 63 | 21 |
| Poverty related | 1.6 | 96 | 61 | 0.5 | 68 | 132 | 0.1 | 9 | 99 | 1.0 | 19 | 20 |
| Other/unknown | 5.9 | 312 | 52 | 2.0 | 222 | 113 | 0.3 | 21 | 66 | 3.6 | 68 | 19 |

- a. Table D.5 includes the beneficiaries represented by Cell G of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Washington, 0.3 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all combined. For information about this classification method, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).
- d. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- e. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE D.6

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY^{a, b, c, d}

DUAL ELIGIBLE BENEFICIARIES. WASHINGTON. 2004

| | | er of Rx nth Amo | • | | \$ per E | Benefit M Use | | nong | | \$ pe | r Rx | | | | | Users ^e | |
|------------------------------------------------------------------|-------|------------------------|--------------------------|---------|----------|------------------------|--------------------------|---------|-------|------------------------|--------------------------|---------|-----------------------|--------------|--------|----------------------------------------|--------------------------------|
| Therapeutic Category | Total | Patented Brand-Name | Off-Patent Brand-Name | Generic | Total | Patented Brand-Name | Off-Patent Brand-Name | Generic | Total | Patented Brand-Name | Off-Patent Brand-Name | Generic | Total Number of Rx | Total Rx \$ | Number | As a Percentage of Dual Benes | Number of Benefit Months |
| Anti-infective Agents | 0.4 | 0.1 | 0.0 | 0.2 | \$30 | \$22 | \$2 | \$6 | \$80 | \$182 | \$97 | \$24 | 222,521 | \$17,752,932 | 53,914 | 53.1 % | 599,279 |
| Biologicals | 0.1 | 0.1 | 0.0 | 0.0 | 9 | 2 | 0 | 8 | 91 | 22 | 26 | 278 | 2,155 | 197,088 | 1,898 | 1.9 | 21,598 |
| Antineoplastic Agents | 0.5 | 0.1 | 0.0 | 0.4 | 84 | 55 | 0 | 29 | 154 | 479 | 95 | 68 | 18,425 | 2,842,694 | 3,192 | 3.1 | 33,798 |
| Endocrine/Metabolic Drugs | 1.1 | 0.4 | 0.1 | 0.6 | 46 | 34 | 2 | 10 | 41 | 82 | 25 | 15 | 570,551 | 23,160,319 | 46,370 | 45.6 | 508,462 |
| Cardiovascular Agents | 1.9 | 0.5 | 0.0 | 1.3 | 57 | 37 | 1 | 19 | 30 | 69 | 25 | 14 | 1,285,212 | 38,347,238 | 61,559 | 60.6 | 670,348 |
| Respiratory Agents | 0.7 | 0.4 | 0.0 | 0.3 | 39 | 34 | 0 | 5 | 57 | 89 | 44 | 16 | 280,948 | 16,033,857 | 36,618 | 36.0 | 408,960 |
| Gastrointestinal Agents | 0.7 | 0.3 | 0.0 | 0.3 | 51 | 44 | 1 | 6 | 71 | 127 | 50 | 17 | 354,305 | 25,312,713 | 44,974 | 44.3 | 496,350 |
| Genitourinary Agents | 0.5 | 0.3 | 0.0 | 0.2 | 29 | 24 | 1 | 4 | 54 | 80 | 48 | 20 | 97,226 | 5,223,876 | 16,149 | 15.9 | 179,268 |
| CNS Drugs | 1.4 | 0.6 | 0.1 | 0.8 | 118 | 93 | 6 | 19 | 84 | 165 | 79 | 25 | 891,883 | 74,785,707 | 58,420 | 57.5 | 635,084 |
| Stimulants/Anti-obesity/Anorexia Miscellaneous Psychological/ | 0.7 | 0.2 | 0.0 | 0.4 | 53 | 32 | 3 | 18 | 79 | 130 | 101 | 46 | 10,151 | 798,661 | 1,373 | 1.4 | 15,204 |
| Neurological Agents | 0.8 | 0.8 | 0.0 | 0.0 | 158 | 158 | 0 | 0 | 204 | 206 | 0 | 14 | 44,779 | 9,151,617 | 5,450 | 5.4 | 57,808 |
| Analgesics and Anesthetics | 0.9 | 0.2 | 0.0 | 0.7 | 46 | 29 | 2 | 15 | 51 | 145 | 211 | 21 | 566,149 | 28,807,070 | 57,080 | 56.2 | 625,773 |
| Neuromuscular Agents | 1.0 | 0.3 | 0.2 | 0.5 | 79 | 40 | 25 | 15 | 80 | 145 | 125 | 29 | 361,105 | 28,751,438 | 32,619 | 32.1 | 361,662 |
| Nutritional Products | 0.7 | 0.0 | 0.0 | 0.6 | 12 | 0 | 1 | 11 | 18 | 16 | 15 | 18 | 132,216 | 2,318,032 | 18,759 | 18.5 | 201,192 |
| Hematological Agents | 0.8 | 0.3 | 0.1 | 0.5 | 60 | 52 | 2 | 6 | 71 | 201 | 27 | 12 | 152,585 | 10,902,102 | 16,963 | 16.7 | 181,283 |
| Topical Products | 0.4 | 0.1 | 0.0 | 0.3 | 18 | 11 | 1 | 6 | 42 | 77 | 53 | 22 | 202,484 | 8,426,317 | 41,709 | 41.1 | 469,707 |
| Miscellaneous Products | 0.2 | 0.1 | 0.0 | 0.1 | 35 | 24 | 3 | 7 | 145 | 213 | 283 | 64 | 8,160 | 1,181,859 | 3,046 | 3.0 | 33,772 |
| Unknown Therapeutic Category | 0.3 | 0.0 | 0.0 | 0.0 | 6 | 0 | 0 | 0 | 20 | 0 | 0 | 0 | 11,589 | 235,768 | 3,277 | 3.2 | 36,799 |
| TOTAL NO. OF RX AND RX \$ | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | 5,212,444 | 294,229,288 | n.a. | n.a. | n.a. |

- a. Table D.6 includes the beneficiaries represented by Cell G of Table 1. A beneficiary who used drugs from two or more categories was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. For information about these therapeutic categories, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).
- d. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Washington, 0.3 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined. For information about this classification method, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).
- e. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2004.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE D.7

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP^{9, b, c}

DUAL ELIGIBLE BENEFICIARIES, WASHINGTON, 2004

| | | | Users | | Ar | nong Users | |
|--------------------------------|--------------------------|--------------------|---------------------------------------|-----------------------------|--------------------------------------|------------|-------------------------|
| Top 10 Drug Groups | Total Medicaid Rx \$ | Number of Users | As a Percentage of Dual Beneficiaries | Number of Benefit Months | Number of Rx per Benefit Month | Rx : | \$ per Benefit Month |
| ANTIPSYCHOTICS | \$47,534,380 | 29,722 | 29.3 % | 327,859 | 0.8 | \$187 | \$145 |
| ANTIDEPRESSANTS | 24,546,002 | 60,154 | 59.2 | 660,833 | 0.7 | 54 | 37 |
| ANTICONVULSANT | 24,116,508 | 26,405 | 26.0 | 294,105 | 0.8 | 101 | 82 |
| ULCER DRUGS | 20,321,675 | 46,175 | 45.5 | 513,352 | 0.6 | 65 | 40 |
| ANALGESICS - Narcotic | 15,624,252 | 67,928 | 66.9 | 749,001 | 0.5 | 43 | 21 |
| ANTIHYPERLIPIDEMIC | 15,381,386 | 28,400 | 28.0 | 319,375 | 0.7 | 68 | 48 |
| ANTIDIABETIC | 13,765,334 | 32,656 | 32.1 | 361,211 | 0.8 | 50 | 38 |
| ANTIASTHMATIC | 12,145,713 | 37,234 | 36.7 | 414,567 | 0.4 | 67 | 29 |
| ANALGESICS - ANTI-INFLAMMATORY | 10,271,971 | 34,729 | 34.2 | 396,475 | 0.4 | 69 | 26 |
| NEUROLOGICAL | 9,149,528 | 6,215 | 6.1 | 66,352 | 0.7 | 204 | 138 |
| Total | 192,856,749 | 369,618 | | 4,103,130 | n.a. | n.a. | n.a. |

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement; n.a. = not applicable.

a. Table D.7 includes the beneficiaries represented by Cell G of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2004. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

TABLE D.7A

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS COMBINED

AND FIRST AND SECOND GROUPS SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c}

DUAL ELIGIBLE BENEFICIARIES, WASHINGTON, 2004

| | All Top 10 D | rug Groups | | ANTIPS | YCHOTICS | | | | ANTIDE | PRESSANTS | | |
|----------------------------------------|--------------|---------------|--------------------|-----------------------------------|--------------------------------------------------|----------------------------------|-------|--------------------|-----------------------------------|--------------------------------------------------|-------|---------------------------------------|
| Beneficiary Characteristics | Number of Rx | Rx \$ | Number of Users | Users as % of Dual Benes | Number of Benefit Months Among Users | of Rx per Benefit Month | Month | Number of Users | Users as % of Dual Benes | Number of Benefit Months Among Users | of Rx | Mean Rx \$ per Benefit Month |
| All | 2,505,817 | \$192,856,749 | 29,722 | 29.3 % | 327,859 | 0.8 | \$145 | 60,154 | 59.2 % | 660,833 | 0.7 | \$37 |
| Female | 1,688,590 | 122,792,540 | 17,118 | 27.0 | 188,212 | 0.7 | 123 | 42,094 | 66.4 | 463,415 | 0.7 | 38 |
| Disabled | 708,296 | 61,496,054 | 8,665 | 38.8 | 98,710 | 8.0 | 145 | 19,202 | 86.1 | 217,368 | 0.7 | 41 |
| 5 and younger | 39 | 2,675 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 6-14 | 62 | 2,725 | 0 | 0.0 | 0 | 0.0 | 0 | 1 | 12.5 | 12 | 1.0 | 67 |
| 15-20 | 649 | 53,810 | 19 | 27.1 | 221 | 0.4 | 79 | 31 | 44.3 | 367 | 0.6 | 34 |
| 21-44 | 205,082 | 19,269,434 | 3,729 | 45.0 | 42,426 | 0.7 | 139 | 6,335 | 76.4 | 71,523 | 0.6 | 41 |
| 45-64 | 500,929 | 42,088,795 | 4,905 | 35.4 | 55,950 | 0.8 | 150 | 12,795 | 92.3 | 145,114 | 0.7 | 42 |
| 65-74 | 1,535 | 78,615 | 12 | 15.4 | 113 | 1.1 | 47 | 40 | 51.3 | 352 | 0.7 | 36 |
| 75-84 | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 85 and older Other Eligibles | 980,294 | 61,296,486 | 8,453 | 20.6 | 89,502 | 0.7 | 99 | 22,892 | 55.7 | 246,047 | 0.7 | 34 |
| 5 and younger | 13 | 732 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 6-14 | 1 | 5 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 15-20 | 63 | 2,870 | 1 | 11.1 | 9 | 0.1 | 1 | 1 | 11.1 | 12 | 0.9 | 13 |
| 21-44 | 2,954 | 216,216 | 59 | 13.8 | 558 | 0.4 | 78 | 176 | 41.3 | 1,440 | 0.4 | 31 |
| 45-64 | 1,238 | 115,126 | 14 | 13.6 | 105 | 0.7 | 144 | 54 | 52.4 | 411 | 0.6 | 43 |
| 65-74 | 361,643 | 23,648,472 | 2,117 | 15.6 | 23,534 | 0.7 | 113 | 7,444 | 54.9 | 83,728 | 0.7 | 33 |
| 75-84 | 360,386 | 22,352,096 | 3,098 | 21.5 | 33,013 | 0.7 | 101 | 8,007 | 55.7 | 86,276 | 0.7 | 34 |
| 85 and older | 253,996 | 14,960,969 | 3,164 | 25.1 | 32,283 | 0.7 | 87 | 7,210 | 57.3 | 74,180 | 8.0 | 35 |
| Male | 817,227 | 70,064,209 | 12,604 | 33.0 | 139,647 | 0.8 | 174 | 18,060 | 47.3 | 197,418 | 0.7 | 36 |
| Disabled | 491,562 | 49,697,750 | 9,706 | 45.4 | 110,064 | 0.9 | 193 | 11,244 | 52.5 | 126,140 | 0.7 | 39 |
| Disabled | 34 | 1,736 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 5 and younger | 11 | 519 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 6-14 | 744 | 91,068 | 26 | 28.6 | 312 | 0.7 | 167 | 18 | 19.8 | 210 | 0.7 | 50 |
| 15-20 | 206,910 | 23,386,840 | 5,382 | 50.3 | 61,141 | 0.8 | 190 | 5,275 | 49.3 | 59,708 | 0.6 | 39 |
| 21-44 | 282,877 | 26,149,223 | 4,287 | 40.8 | 48,513 | 0.9 | 197 | 5,927 | 56.3 | 65,981 | 0.7 | 39 |
| 45-64 | 986 | 68,364 | 11 | 15.7 | 98 | 0.9 | 195 | 24 | 34.3 | 241 | 0.6 | 35 |
| 65-74 | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 75-84 | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 85 and older Other Eligibles | 325,665 | 20,366,459 | 2,898 | 17.2 | 29,583 | 0.7 | 105 | 6,816 | 40.5 | 71,278 | 0.7 | 32 |
| | 7 | 231 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 5 and younger | 10 | 849 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 6-14 | 7 | 902 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 15-20 | 1,848 | 142,828 | 32 | 18.7 | 299 | 0.4 | 60 | 87 | 50.9 | 745 | 0.5 | 27 |
| 21-44 | 907 | 93,178 | 11 | 12.5 | 91 | 0.5 | 65 | 43 | 48.9 | 289 | 0.4 | 27 |
| 45-64 | 155,378 | 9,979,927 | 1,007 | 13.3 | 10,892 | 0.8 | 137 | 2,819 | 37.2 | 31,298 | 0.6 | 30 |
| 65-74 | 115,446 | 7,066,466 | 1,092 | 18.5 | 11,055 | 0.7 | 91 | 2,404 | 40.7 | 24,903 | 0.7 | 33 |
| 75-84 | 52,062 | 3,082,078 | 756 | 24.7 | 7,246 | 0.7 | 81 | 1,463 | 47.7 | 14,043 | 0.7 | 33 |
| 85 and older | | _ | | | | | _ | | | _ | | |
| Unknown | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |

- a. Table D.7A includes the beneficiaries represented by Cell G of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2004. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE D.7B

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR THIRD TO FIFTH TOP DRUG GROUPS

SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c}

DUAL ELIGIBLE BENEFICIARIES, WASHINGTON, 2004

| | | ANTIC | ONVULSANT | | | | ULCE | R DRUGS | | | | ANALGES | SICS - Narcoti | С | |
|----------------------------------------|--------------------|-----------------------------------|--------------------------------------------------|-------|---------------------------------------|--------------------|-----------------------------------|--------------------------------------------------|-------|---------------------------------------|--------------------|-----------------------------------|--------------------------------------------------|-------|-------------------|
| Beneficiary Characteristics | Number of Users | Users as % of Dual Benes | Number of Benefit Months Among Users | of Rx | Mean Rx \$ per Benefit Month | Number of Users | Users as % of Dual Benes | Number of Benefit Months Among Users | of Rx | Mean Rx \$ per Benefit Month | Number of Users | Users as % of Dual Benes | Number of Benefit Months Among Users | of Rx | Mean Rx \$ per |
| All | 26,405 | 26.0 % | 294,105 | 0.8 | \$82 | 46,175 | 45.5 % | 513,352 | 0.6 | \$40 | 67,928 | 66.9 % | 749,001 | 0.5 | |
| Female | 16,644 | 26.3 | 185,375 | 0.8 | 79 | 32,130 | 50.7 | 357,913 | 0.6 | 40 | 47,120 | 74.4 | 520,751 | 0.5 | 21 |
| Disabled | 9,529 | 42.7 | 108,213 | 0.8 | 97 | 11,093 | 49.7 | 126,322 | 0.6 | 41 | 20,686 | 92.7 | 235,564 | 0.5 | 26 |
| | 0 | 0.0 | 0 | 0.0 | 0 | 2 | 50.0 | 24 | 1.0 | 69 | 1 | 25.0 | 12 | 0.1 | C |
| 5 and younger | 1 | 12.5 | 12 | 0.7 | 5 | 5 | 62.5 | 60 | 0.7 | 31 | 2 | 25.0 | 24 | 0.1 | 1 |
| 6-14 | 13 | 18.6 | 153 | 0.7 | 96 | 14 | 20.0 | 158 | 0.5 | 32 | 34 | 48.6 | 375 | 0.2 | 2 |
| 15-20 | 3,722 | 44.9 | 42,134 | 8.0 | 102 | 3,181 | 38.4 | 36,159 | 0.5 | 34 | 6,990 | 84.3 | 79,715 | 0.5 | 21 |
| 21-44 | 5,780 | 41.7 | 65,788 | 8.0 | 94 | 7,867 | 56.8 | 89,721 | 0.6 | 44 | 13,616 | 98.3 | 155,065 | 0.6 | 29 |
| 45-64 | 13 | 16.7 | 126 | 1.0 | 47 | 24 | 30.8 | 200 | 0.7 | 39 | 43 | 55.1 | 373 | 0.7 | 21 |
| 65-74 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | (|
| 75-84 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | (|
| 85 and older Other Eligibles | 7,115 | 17.3 | 77,162 | 0.8 | 53 | 21,037 | 51.2 | 231,591 | 0.6 | 40 | 26,434 | 64.4 | 285,187 | 0.5 | 17 |
| | 0 | 0.0 | 0 | 0.0 | 0 | 2 | 200.0 | 24 | 0.4 | 30 | 2 | 200.0 | 24 | 0.1 | 1 |
| 5 and younger | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 1 | 25.0 | 12 | 0.1 | (|
| 6-14 | 2 | 22.2 | 22 | 0.8 | 41 | 4 | 44.4 | 30 | 0.3 | 23 | 4 | 44.4 | 33 | 0.5 | 15 |
| 15-20 | 78 | 18.3 | 657 | 0.6 | 76 | 78 | 18.3 | 711 | 0.3 | 19 | 279 | 65.5 | 2,427 | 0.4 | 10 |
| 21-44 | 26 | 25.2 | 201 | 0.7 | 75 | 27 | 26.2 | 219 | 0.5 | 27 | 57 | 55.3 | 468 | 0.7 | 54 |
| 45-64 | 2,667 | 19.7 | 29,949 | 0.7 | 64 | 7,569 | 55.8 | 86,371 | 0.6 | 40 | 9,229 | 68.1 | 104,419 | 0.5 | 17 |
| 65-74 | 2,669 | 18.6 | 28,860 | 0.8 | 48 | 7,516 | 52.3 | 83,009 | 0.6 | 40 | 9,133 | 63.5 | 99,305 | 0.5 | 16 |
| 75-84 | 1,673 | 13.3 | 17,473 | 0.8 | 41 | 5,841 | 46.4 | 61,227 | 0.7 | 39 | 7,729 | 61.4 | 78,499 | 0.5 | 18 |
| 85 and older | 0.704 | 05.5 | 400 700 | 0.0 | 00 | 44.045 | 00.0 | 455 400 | 0.0 | 00 | 00.000 | 5.4.F | 000.050 | 0.5 | 00 |
| Male | 9,761 | 25.5 | 108,730 | 0.8 | 88 | 14,045 | 36.8 | 155,439 | 0.6 | 39 | 20,808 | 54.5 | 228,250 | 0.5 | |
| Disabled | 7,301 | 34.1 | 82,716 | 0.9 | 98 | 6,799 | 31.8 | 76,927 | 0.6 | 40 | 12,613 | 58.9 | 141,841 | 0.5 | 24 |
| 5 and younger | 1 | 33.3 | 12 | 0.6 | 16 | 1 | 33.3 | 12 | 0.2 | 16 | 1 | 33.3 | 12 | 0.1 | 1 |
| 6-14 | 0 | 0.0 | 0 | 0.0 | 0 | 1 | 16.7 | 12 | 0.2 | 9 | 2 | 33.3 | 24 | 0.1 | 1 |
| 15-20 | 18 | 19.8 | 216 | 0.6 | 86 | 13 | 14.3 | 153 | 0.3 | 26 | 39 | 42.9 | 455 | 0.2 | |
| 21-44 | 3,542 | 33.1 | 40,299 | 0.8 | 104 | 2,762 | 25.8 | 31,624 | 0.6 | 38 | 5,898 | 55.1 | 67,068 | 0.4 | 19 |
| 45-64 | 3,727 | 35.4 | 42,068 | 0.9 | 94 | 4,001 | 38.0 | 44,936 | 0.6 | 42 | 6,635 | 63.1 | 74,006 | 0.5 | 29 |
| 65-74 | 13 | 18.6 | 121 | 0.8 | 63 | 21 | 30.0 | 190 | 0.7 | 53 | 38 | 54.3 | 276 | 0.7 | 18 |
| 75-84 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | |
| | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | C |
| 85 and older Other Eligibles | 2,460 | 14.6 | 26,014 | 0.7 | 54 | 7,246 | 43.1 | 78,512 | 0.6 | 37 | 8,195 | 48.7 | 86,409 | 0.4 | 14 |
| 5 and younger | 0 | 0.0 | 0 | 0.0 | 0 | 1 | 100.0 | 12 | 0.5 | 18 | 1 | 100.0 | 12 | 0.1 | 1 |
| 6-14 | 0 | 0.0 | 0 | 0.0 | 0 | 1 | 50.0 | 12 | 0.8 | 71 | 0 | 0.0 | 0 | 0.0 | C |
| 15-20 | 0 | 0.0 | 0 | 0.0 | 0 | 1 | 25.0 | 12 | 0.6 | 75 25 | 0 | 0.0 | 0 | 0.0 | 0 |
| 21-44 | 45 45 | 26.3 | 388 | 0.6 | 69 | 45 | 26.3 | 394 | 0.5 | 35 | 112 | 65.5 | 1,001 | 0.5 | 23 |
| 45-64 | 15 | 17.0 | 107 | 0.5 | 62 | 10 | 11.4 | 92 | 0.3 | 24 | 57 | 64.8 | 431 | 0.8 | 117 |
| 65-74 | 1,144 | 15.1 | 12,596 | 0.7 | 61 | 3,286 | 43.4 | 36,844 | 0.6 | 37 | 3,761 | 49.7 | 41,773 | 0.4 | 14 |
| 75-84 | 870 | 14.7 | 9,100 | 0.7 | 48 | 2,649 | 44.9 | 28,651 | 0.6 | 37 | 2,725 | 46.1 | 28,584 | 0.4 | 12 |
| 85 and older | 386 | 12.6 | 3,823 | 8.0 | 41 | 1,253 | 40.9 | 12,495 | 0.7 | 39 | 1,539 | 50.2 | 14,608 | 0.4 | 12 |
| Unknown | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | C |

- a. Table D.7B includes the beneficiaries represented by Cell G of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2004. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE D.7C

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR SIXTH TO EIGHTH TOP DRUG GROUPS

SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c}

DUAL ELIGIBLE BENEFICIARIES, WASHINGTON, 2004

| Beneficiary Number of Parish Series Number of Number o | | | ANTIHYF | PERLIPIDEMIC | | | | ANTI | DIABETIC | | | | ANTIA | STHMATIC | | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|--------|--------------------------|-------------------------------------|--------------------------------------------|-------------------------------|--------|--------------------------|-------------------------------------|--------------------------------------------|-------------------------------|--------|--------------------------|-------------------------------------|--------------------------------------------|-------------------------------|
| Pemale | Characteristics | Users | as % of Dual Benes | Benefit Months Among Users | Number of Rx per Benefit Month | Rx \$ per Benefit Month | Users | as % of Dual Benes | Benefit Months Among Users | Number of Rx per Benefit Month | Rx \$ per Benefit Month | Users | as % of Dual Benes | Benefit Months Among Users | Number of Rx per Benefit Month | Rx \$ per Benefit Month |
| Disabled 5,78 | All | 28,400 | 28.0 % | 319,375 | 0.7 | \$48 | 32,656 | 32.1 % | 361,211 | 0.8 | \$38 | 37,234 | 36.7 % | 414,567 | 0.4 | \$29 |
| 5 and younger 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 < | Female | 18,533 | 29.2 | 208,893 | 0.7 | 48 | 21,991 | 34.7 | 244,571 | 0.8 | 38 | 25,485 | 40.2 | 285,006 | 0.4 | 29 |
| 6 and younger 0 0 0 0 0 0 0 0 0 0 0 0 1 12.5 12 0.1 15-20 914 11.0 10.466 0.6 42 1.321 15.9 15.066 0.7 42 3.145 37.9 36.003 0.3 21-144 4.796 34.6 54.819 0.7 43 55.54 40.1 62.904 0.8 47 7.720 55.7 97.942 0.4 65-74 25 32.1 200 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 | Disabled | , | | • | | | , | | , | | | | | | | 27 |
| 6-14 | 5 and vounger | | | | | | | | | | | | | | | 28 |
| 15-20 | , , | | | | | | | | | | | | | | | 1 |
| 21-44 | | | | | | | | | | | | | | | | |
| 4-564 | | | | -, | | | , - | | - / | | | -, - | | , | | 22 |
| | | , | | • | | | , | | , | | | · | | | | 29 |
| 75-94 0 0 0.0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | | | | | | | | | | | | | | | | 51 |
| Sand older 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | | | | | | | | | | | | | | | | 0 |
| 5 and younger 0 0.0 0 0.0 0 0 0.0 0 0 0.0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | | | | | | | | | | | | | | | | 0 |
| 5 and younger 0 0.0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | Other Eligibles | , | | • | | _ | -, | | , | | | , | | , - | | 30 |
| 6-14 0 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0. | 5 and vounger | - | | | | | | | | | | | | - | | |
| 15-20 1 11.1 3 0.7 4.5 4.5 24 30 7.0 257 0.4 35 99 23.2 867 0.3 21-44 17 16.5 16.4 0.6 42 2.4 3.3 194 0.8 55 18 17.5 12.9 0.3 21-44 4.5 64 5.9 4.5 5.5 4.8 67.8 4.5 5.5 18 67.5 12.9 0.3 21.4 4.5 64 5.9 4.5 5.5 4.8 67.8 4.5 5.5 4.8 68.4 4.5 64 5.5 65.4 4.5 5.5 4.8 68.4 4.5 68.4 5.5 65.4 4.5 5.5 4.8 68.4 4.5 68.4 5.5 65.4 4.5 5.5 4.8 5.5 64.9 0.7 4.8 5.7 4.0 21.8 28.4 6.0 8.3 3.5 5.6 6.0 35.2 55.8 4.0 0.4 65.3 65.4 65.7 4.5 65.4 6.0 6.0 4.5 65.4 6.0 6.0 4.5 65.4 6.0 6.0 4.5 65.4 6.0 6.0 4.5 65.4 6.0 6.0 4.5 65.4 6.0 6.0 4.5 65.4 6.0 6.0 4.5 65.4 6.0 6.0 4.5 65.4 6.0 4.5 65.4 6.0 6.0 4.5 65.4 6.0 6.0 4.5 65.4 6.0 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 6.0 4.5 65.4 | , , | | | | | | | | | | | | | | | |
| 21-44 | | · · | | | | | | | | | | | | | | 0 |
| 45-64 | | | | | | | | | | | | | | | | 13 |
| 65-74 | 45-64 | | | | | | | | | | | _ | | | | 11 |
| 75-84 1,872 14.9 19,870 0.8 47 2,740 21.8 28,496 0.8 28 3,331 26.5 35,135 0.4 Male 9,867 25.8 110,482 0.7 49 10,665 27.9 116,640 0.8 38 11,749 30.7 129,561 0.5 Disabled 4,353 20.3 49,429 0.7 49 4,572 21.4 50,991 0.8 45 5,559 26.0 62,673 0.4 5 and younger 0 0.0 0 0 0 0 0 0 0 0 0 0 22 33.3 24 0.3 6-14 6 6.6 6.9 0.7 60 1 1.1 12 0.2 2 12 13.2 144 0.1 15-20 1,280 12.0 14,624 0.6 45 1,262 11.8 14,20 0.8 44 3,474 33.0< | 65-74 | -, | | - , | | | - / | _ | -, | | | - , - | | , - | | 32 |
| 85 and older Male 9,867 25.8 110,482 0.7 49 10,665 27.9 116,640 0.8 38 11,749 30.7 129,561 0.5 Disabled 4,355 20.3 49,429 0.7 49 4,572 21.4 50,991 0.8 45 5,559 26.0 62,673 0.4 5 and younger 0 0 0.0 0 0 0.0 0 0 0 0 0 0 0 0 0 0 0 | 75-84 | , | | , | | | , | | • | | | , | | | | 31 |
| Disabled 4,353 20.3 49,429 0.7 49 4,572 21.4 50,991 0.8 45 5,559 26.0 62,673 0.4 5 and younger 0 0.0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | 85 and older | 1,872 | 14.9 | 19,870 | 0.8 | 47 | 2,740 | 21.8 | 28,496 | 0.8 | 28 | 3,331 | 20.5 | 35,135 | 0.4 | 25 |
| 5 and younger 0 0.0 0 0 0.0 0 0.0 0 0 0.0 3 100.0 36 0.7 6-14 6 6.6 69 0.7 60 1 1.1 12 0.2 2 12 13.2 144 0.1 15-20 1,280 12.0 14,624 0.6 45 1,262 11.8 14,240 0.8 46 2,052 19.2 23,338 0.4 21-44 3,054 29.0 34,616 0.7 51 3,288 31.3 36,565 0.8 44 3,474 33.0 39,011 0.5 45-64 13 18.6 120 0.7 46 21 30.0 174 0.6 32 16 22.9 120 0.5 65-74 0 0.0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 <td< td=""><td>Male</td><td>9,867</td><td>25.8</td><td>110,482</td><td>0.7</td><td>49</td><td>10,665</td><td>27.9</td><td>116,640</td><td>0.8</td><td>38</td><td>11,749</td><td>30.7</td><td>129,561</td><td>0.5</td><td>31</td></td<> | Male | 9,867 | 25.8 | 110,482 | 0.7 | 49 | 10,665 | 27.9 | 116,640 | 0.8 | 38 | 11,749 | 30.7 | 129,561 | 0.5 | 31 |
| 5 and younger 0 0.0 0 0 0.0 0 0.0 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 33.3 24 0.3 6-14 6 6.6 6.6 0.0 0.7 60 45 1.26 11.8 14.240 0.8 46 2.052 19.2 23,338 0.4 21-44 3.054 29.0 34,616 0.7 51 3,288 31.3 36,565 0.8 44 3,474 33.0 39,011 0.5 65-74 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 | Disabled | 4,353 | 20.3 | 49,429 | 0.7 | 49 | 4,572 | 21.4 | 50,991 | 0.8 | 45 | 5,559 | 26.0 | 62,673 | 0.4 | 29 |
| 6-14 6 6 6.6 69 0.7 60 1 1.11 12 0.2 2 2 11 13.2 144 0.1 15-20 1,280 12.0 14,624 0.6 45 1,262 11.8 14,240 0.8 46 2,052 19.2 23,338 0.4 21-44 33,054 29.0 34,616 0.7 51 3,288 31.3 36,565 0.8 44 3,474 33.0 39,011 0.5 45-64 13 18.6 120 0.7 46 21 30.0 174 0.6 32 16 22.9 120 0.5 65-74 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0. | | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 3 | 100.0 | 36 | 0.7 | 38 |
| 15-20 | | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 2 | 33.3 | 24 | 0.3 | 17 |
| 21-44 3,054 29.0 34,616 0.7 51 3,288 31.3 36,565 0.8 44 3,474 33.0 39,011 0.5 45-64 13 18.6 120 0.7 46 21 30.0 174 0.6 32 16 22.9 120 0.5 65-74 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 | | 6 | 6.6 | 69 | 0.7 | 60 | 1 | 1.1 | 12 | 0.2 | 2 | 12 | 13.2 | 144 | 0.1 | 3 |
| 45-64 13 18.6 120 0.7 46 21 30.0 174 0.6 32 16 22.9 120 0.5 65-74 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 | | 1,280 | 12.0 | 14,624 | 0.6 | 45 | 1,262 | 11.8 | 14,240 | 0.8 | 46 | 2,052 | 19.2 | 23,338 | 0.4 | 22 |
| 65-74 | | 3,054 | 29.0 | 34,616 | 0.7 | 51 | 3,288 | 31.3 | 36,565 | 0.8 | 44 | 3,474 | 33.0 | 39,011 | 0.5 | 34 |
| 75-84 0 0 0.0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | | 13 | 18.6 | 120 | 0.7 | 46 | 21 | 30.0 | 174 | 0.6 | 32 | 16 | 22.9 | 120 | 0.5 | 32 |
| 85 and older Cither Eligibles 5,514 32.8 61,053 0.7 48 6,093 36.2 65,649 0.8 33 6,190 36.8 66,888 0.5 5 and younger 0 0.0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 <td< td=""><td></td><td>0</td><td>0.0</td><td>0</td><td>0.0</td><td>0</td><td>0</td><td>0.0</td><td>0</td><td>0.0</td><td>0</td><td>0</td><td>0.0</td><td>0</td><td>0.0</td><td>0</td></td<> | | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 5 and younger 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0. | | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 5 and younger 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0. | Other Eligibles | 5,514 | 32.8 | 61,053 | 0.7 | 48 | 6,093 | 36.2 | 65,649 | 0.8 | 33 | 6,190 | 36.8 | 66,888 | 0.5 | 32 |
| 6-14 0 0 0.0 0 0 0.0 0 0 0 0 0 0 0 0 0 0 0 | • | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 15-20 18 10.5 149 0.7 43 14 8.2 88 0.8 30 43 25.1 408 0.3 21-44 20 22.7 143 0.6 59 30 34.1 242 0.6 35 9 10.2 68 0.2 45-64 3,001 39.6 33,895 0.7 48 3,112 41.1 34,528 0.8 37 2,938 38.8 33,014 0.5 65-74 1,955 33.1 21,532 0.7 48 2,153 36.5 23,145 0.8 31 2,194 37.2 23,452 0.5 75-84 520 17.0 5,334 0.7 44 784 25.6 7,646 0.7 26 1,006 32.8 9,946 0.4 85 and older | , , | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 21-44 20 22.7 143 0.6 59 30 34.1 242 0.6 35 9 10.2 68 0.2 45-64 3,001 39.6 33,895 0.7 48 3,112 41.1 34,528 0.8 37 2,938 38.8 33,014 0.5 65-74 1,955 33.1 21,532 0.7 48 2,153 36.5 23,145 0.8 31 2,194 37.2 23,452 0.5 75-84 520 17.0 5,334 0.7 44 784 25.6 7,646 0.7 26 1,006 32.8 9,946 0.4 85 and older | | | | | 0.0 | | 0 | | | 0.0 | | - | 0.0 | 0 | | 0 |
| 45-64 3,001 39.6 33,895 0.7 48 3,112 41.1 34,528 0.8 37 2,938 38.8 33,014 0.5 65-74 1,955 33.1 21,532 0.7 48 2,153 36.5 23,145 0.8 31 2,194 37.2 23,452 0.5 75-84 520 17.0 5,334 0.7 44 784 25.6 7,646 0.7 26 1,006 32.8 9,946 0.4 85 and older | | _ | | | 0.7 | | | 8.2 | | | | | | | | 19 |
| 3,001 39.6 33,895 0.7 48 3,112 41.1 34,528 0.8 37 2,938 38.8 33,014 0.5 65-74 1,955 33.1 21,532 0.7 48 2,153 36.5 23,145 0.8 31 2,194 37.2 23,452 0.5 75-84 520 17.0 5,334 0.7 44 784 25.6 7,646 0.7 26 1,006 32.8 9,946 0.4 85 and older | | 20 | 22.7 | 143 | 0.6 | 59 | 30 | 34.1 | 242 | 0.6 | | 9 | 10.2 | 68 | 0.2 | |
| 75-84 520 17.0 5,334 0.7 44 784 25.6 7,646 0.7 26 1,006 32.8 9,946 0.4 85 and older | | 3,001 | 39.6 | 33,895 | 0.7 | 48 | 3,112 | 41.1 | 34,528 | 0.8 | 37 | 2,938 | | 33,014 | 0.5 | 35 |
| 520 17.0 5,334 0.7 44 784 25.6 7,046 0.7 26 1,006 32.8 9,946 0.4 85 and older | | 1,955 | 33.1 | 21,532 | 0.7 | 48 | 2,153 | 36.5 | 23,145 | 0.8 | 31 | 2,194 | 37.2 | 23,452 | 0.5 | 31 |
| | | 520 | 17.0 | 5,334 | 0.7 | 44 | 784 | 25.6 | 7,646 | 0.7 | 26 | 1,006 | 32.8 | 9,946 | 0.4 | 28 |
| Unknown 0 0.0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0 | | 0 | 0.0 | Λ | 0.0 | Ω | 0 | 0.0 | Λ | 0.0 | Ω | 0 | 0.0 | Λ | 0.0 | 0 |

- a. Table D.7C includes the beneficiaries represented by Cell G of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2004. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE D.7D MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR NINTH AND TENTH TOP DRUG GROUPS SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c} DUAL ELIGIBLE BENEFICIARIES, WASHINGTON, 2004

| | ANAL | GESICS - A | NTI-INFLAM | MATORY | | MISC PSYCH | OTHERAPI | EUTIC AND I | NEUROLO | OGICAL | | |
|----------------------------------------|-----------------|-----------------------------------|--------------------------------------------------|----------------------------------|----------|--------------------|-----------------------------------|--------------------------------------------------|------------|-----------|------------------------------|-----------|
| Beneficiary Characteristics | Number of Users | Users as % of Dual Benes | Number of Benefit Months Among Users | of Rx per Benefit Month | Month | Number of Users | Users as % of Dual Benes | Number of Benefit Months Among Users | of Rx | Month | Number of Beneficiaries E | |
| All | 34,729 | 34.2 % | 396,475 | 0.4 | \$26 | 6,215 | 6.1 % | 66,352 | 0.7 | \$138 | 101,583 | 1,079,506 |
| Female | 24,213 | 38.2 | 276,807 | 0.4 | 29 | 4,522 | 7.1 | 48,718 | 0.7 | 139 | 63,373 | 674,881 |
| Disabled | 10,215 | 45.8 | 117,600 | 0.4 | 28 | 508 | 2.3 | 5,864 | 0.7 | 490 | 22,308 | 246,370 |
| 5 and younger | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 4 | 40 |
| 6-14 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 8 | 90 |
| 15-20 | 15 | 21.4 | 168 | 0.1 | 2 | 1 | 1.4 | 12 | 0.1 | 19 | 70 | 773 |
| 21-44 | 3,335 | 40.2 | 38,338 | 0.3 | 18 | 127 | 1.5 | 1,459 | 0.6 | 472 | 8,293 | 91,602 |
| 45-64 | 6,841 | 49.4 | 78,846 | 0.4 | 33 | 379 | 2.7 | 4,385 | 0.7 | 498 | 13,855 | 153,286 |
| 65-74 | 24 | 30.8 | 248 | 0.5 | 29 | 1 | 1.3 | 8 | 0.4 | 30 | 78 | 579 |
| 75-84 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0 |
| 85 and older | • | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0 |
| 85 and older Other Eligibles | 13,998 | 34.1 | 159,207 | 0.4 | 30 | 4,014 | 9.8 | 42,854 | 0.7 | 91 | 41,065 | 428,511 |
| 5 and younger | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 1 | 12 |
| 6-14 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 4 | 43 |
| 15-20 | 2 | 22.2 | 21 | 0.1 | 1 | 0 | 0.0 | 0 | 0.0 | 0 247 | 9 | 84 |
| 21-44 | 84 | 19.7 | 765 | 0.2 | 16 | | 0.7 | 28 | 0.3 | | 426 | 3,282 |
| 45-64 | 31 | 30.1 44.2 | 230 | 0.3 | 47 30 | 1 570 | 1.0 | 12 | 0.4 | 508 | 103 | 730 |
| 65-74 | 5,989 | | 69,507 | 0.4 | 30 | | 4.2 | 6,267 | 0.6 | 122 87 | 13,560 | 148,000 |
| 75-84 | 4,900 | 34.1 23.8 | 56,178 | 0.4 0.5 | 30 29 | 1,718 1,722 | 12.0 13.7 | 18,467 | 0.7 0.7 | 87 85 | 14,376 | 151,621 |
| 85 and older | 2,992 | 23.8 | 32,506 | 0.5 | 29 | 1,722 | 13.7 | 18,080 | 0.7 | 85 | 12,586 | 124,739 |
| Male | 10,516 | 27.5 | 119,668 | 0.3 | 19 | 1,693 | 4.4 | 17,634 | 0.7 | 134 | 38,210 | 404,625 |
| Disabled | 5,870 | 27.4 | 66,880 | 0.3 | 17 | 310 | 1.4 | 3,578 | 0.7 | 331 | 21,398 | 233,080 |
| | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 3 | 36 |
| 5 and younger | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 6 | 62 |
| 6-14 | 19 | 20.9 | 223 | 0.2 | 2 | 0 | 0.0 | 0 | 0.0 | 0 | 91 | 1,033 |
| 15-20 | 2,667 | 24.9 | 30,451 | 0.3 | 14 | 107 | 1.0 | 1,250 | 0.7 | 415 | 10,706 | 117,826 |
| 21-44 | 3,174 | 30.2 | 36,111 | 0.4 | 20 | 201 | 1.9 | 2,312 | 0.7 | 287 | 10,520 | 113,609 |
| 45-64 | 10 | 14.3 | 95 | 0.6 | 26 | 2 | 2.9 | 16 | 0.7 | 61 | 70 | 496 |
| 65-74 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 2 | 18 |
| 75-84 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0 |
| 85 and older Other Eligibles | 4,646 | 27.6 | 52,788 | 0.4 | 20 | 1,383 | 8.2 | 14,056 | 0.7 | 85 | 16,812 | 171,545 |
| _ | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 1 | 12 |
| 5 and younger | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 2 | 14 |
| 6-14 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 4 | 37 |
| 15-20 | 54 | 31.6 | 432 | 0.3 | 55 | 1 | 0.6 | 5 | 0.4 | 130 | 171 | 1,196 |
| 21-44 | 19 | 21.6 | 168 | 0.4 | 17 | 0 | 0.0 | 0 | 0.0 | 0 | 88 | 602 |
| 45-64 | 2,412 | 31.8 | 27,903 | 0.3 | 18 | 278 | 3.7 | 2,964 | 0.6 | 88 | 7,575 | 80,895 |
| 65-74 | 1,577 | 26.7 | 18,099 | 0.4 | 21 | 659 | 11.2 | 6,769 | 0.7 | 84 | 5,905 | 60,219 |
| 75-84 | 584 | 19.0 | 6,186 | 0.4 | 25 | 445 | 14.5 | 4,318 | 0.7 | 83 | 3,066 | 28,570 |
| 85 and older | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0 |
| Unknown | U | 0.0 | U | 0.0 | U | U | 0.0 | U | 0.0 | U | 0 | U |

- a. Table D.7D includes the beneficiaries represented by Cell G of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2004. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy; \$ = Medicaid reimbursement.

TABLE D.8

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,

BY BENEFICIARY CHARACTERISTIC^{a, b}

DUAL ELIGIBLE BENEFICIARIES, WASHINGTON, 2004

| | | | | Benefit Months Among All- |
|-----------------------------------|-------------------------|--------------------------|----------------------------|---------------------------|
| Beneficiary | | Number of Rx per Benefit | Number of All-Year Nursing | Year Nursing Facility |
| Characteristics | Rx \$ per Benefit Month | Month | Facility Residents | Residents |
| All | \$320 | 6.7 | 8,532 | 87,225 |
| Age | | | | |
| 0-64 | 523 | 8.0 | 829 | 9,125 |
| 65-74 | 425 | 7.9 | 982 | 10,250 |
| 75-84 | 320 | 6.9 | 2,770 | 28,063 |
| 85 and older | 246 | 5.9 | 3,951 | 39,787 |
| Unknown | 0 | 0.0 | 0 | 0 |
| Gender | | | | |
| Female | 313 | 6.7 | 6,174 | 63,910 |
| Male | 339 | 6.6 | 2,358 | 23,315 |
| Unknown | 0 | 0.0 | 0 | 0 |
| Race | | | | |
| White | 319 | 6.7 | 7,562 | 77,227 |
| African American | 356 | 6.6 | 201 | 2,166 |
| Other/unknown | 314 | 6.3 | 769 | 7,832 |
| Basis of Eligibility ^c | | | | |
| Aged | 296 | 6.5 | 7,694 | 78,013 |
| Disabled | 522 | 8.0 | 838 | 9,212 |
| Adults | 0 | 0.0 | 0 | 0 |
| Children | 0 | 0.0 | 0 | 0 |
| Unknown | 0 | 0.0 | 0 | 0 |

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy; \$ = Medicaid reimbursement.

a. Table D.8 includes the beneficiaries represented by Cell H of Table 1, those who resided in nursing facilities throughout their 2004 Medicaid enrollment. A total of 7,370 beneficiaries who were in nursing facilities for part of their enrollment and their 69,047 benefit months were excluded from the analysis. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible ebecause of disability or blindness. The children's group includes children receiving foster care and adoptive services.

TABLE D.9

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,

BY BRAND STATUS AND THERAPEUTIC CATEGORY DUAL ELIGIBLE BENEFICIARIES, WASHINGTON, 2004

| | Number of Rx per Benefit \$ per Benefit Mon Month Among Users Among Users | | | | | | | | | \$ per | Rx | | | | | Users | |
|------------------------------------------------------------------|---------------------------------------------------------------------------|-------------------------|---------------------------|---------|-------|-------------------------|---------------------------|---------|-------|-------------------------|---------------------------|---------|-----------------------|-------------|--------------------|--------------------------------------------------------------|--------------------------------|
| Therapeutic Category | Total | Patented Brand- Name | Off-Patent Brand- Name | Generic | Total | Patented Brand- Name | Off-Patent Brand- Name | Generic | Total | Patented Brand- Name | Off-Patent Brand- Name | Generic | Total Number of Rx | Total Rx \$ | Number of Users | As a Percentage of Dual All- Year Nursing Facility Residents | Number of Benefit Months |
| Anti-infective Agents | 0.4 | 0.2 | 0.0 | 0.3 | \$20 | \$14 | \$2 | \$5 | \$47 | \$90 | \$73 | \$19 | 25,936 | \$1,210,684 | 5,681 | 66.6 % | 60,655 |
| Biologicals | 0.1 | 0.0 | 0.0 | 0.1 | 3 | 1 | 0 | 2 | 27 | 25 | 15 | 29 | 310 | 8,374 | 293 | 3.4 | 3,130 |
| Antineoplastic Agents | 0.6 | 0.1 | 0.0 | 0.5 | 88 | 41 | 0 | 47 | 148 | 540 | 51 | 91 | 2,113 | 311,736 | 359 | 4.2 | 3,541 |
| Endocrine/Metabolic Drugs | 1.3 | 0.5 | 0.2 | 0.6 | 44 | 33 | 3 | 8 | 34 | 70 | 19 | 12 | 60,439 | 2,060,436 | 4,507 | 52.8 | 47,150 |
| Cardiovascular Agents | 2.1 | 0.4 | 0.0 | 1.6 | 47 | 25 | 1 | 21 | 23 | 60 | 20 | 13 | 126,401 | 2,861,233 | 5,973 | 70.0 | 61,495 |
| Respiratory Agents | 0.6 | 0.3 | 0.0 | 0.3 | 36 | 30 | 0 | 7 | 59 | 87 | 26 | 25 | 17,088 | 1,012,066 | 2,620 | 30.7 | 27,865 |
| Gastrointestinal Agents | 0.9 | 0.3 | 0.0 | 0.5 | 45 | 35 | 1 | 9 | 52 | 110 | 32 | 18 | 41,086 | 2,135,476 | 4,479 | 52.5 | 47,114 |
| Genitourinary Agents | 0.6 | 0.3 | 0.0 | 0.3 | 30 | 22 | 2 | 7 | 48 | 73 | 41 | 23 | 15,360 | 733,878 | 2,242 | 26.3 | 24,083 |
| CNS Drugs | 1.6 | 0.8 | 0.1 | 0.7 | 117 | 93 | 10 | 15 | 74 | 123 | 71 | 21 | 105,866 | 7,845,292 | 6,402 | 75.0 | 66,781 |
| Stimulants/Anti-obesity/Anorexia Miscellaneous Psychological/ | 8.0 | 0.0 | 0.0 | 8.0 | 16 | 0 | 1 | 15 | 20 | 74 | 28 | 19 | 705 | 13,848 | 80 | 0.9 | 844 |
| Neurological Agents | 0.9 | 0.9 | 0.0 | 0.0 | 142 | 142 | 0 | 0 | 159 | 159 | 0 | 14 | 10,644 | 1,692,741 | 1,149 | 13.5 | 11,911 |
| Analgesics and Anesthetics | 1.2 | 0.3 | 0.0 | 8.0 | 48 | 34 | 1 | 12 | 41 | 105 | 52 | 15 | 57,052 | 2,349,822 | 4,806 | 56.3 | 49,272 |
| Neuromuscular Agents | 1.3 | 0.3 | 0.3 | 0.7 | 82 | 34 | 23 | 25 | 63 | 106 | 88 | 34 | 43,870 | 2,755,625 | 3,133 | 36.7 | 33,661 |
| Nutritional Products | 0.8 | 0.0 | 0.1 | 0.7 | 14 | 0 | 1 | 13 | 17 | 17 | 14 | 18 | 21,201 | 369,172 | 2,594 | 30.4 | 26,764 |
| Hematological Agents | 1.1 | 0.3 | 0.1 | 8.0 | 61 | 52 | 1 | 7 | 53 | 187 | 13 | 10 | 28,491 | 1,507,417 | 2,415 | 28.3 | 24,831 |
| Topical Products | 0.5 | 0.2 | 0.0 | 0.3 | 20 | 12 | 1 | 7 | 39 | 70 | 46 | 22 | 24,479 | 956,093 | 4,434 | 52.0 | 48,169 |
| Miscellaneous Products | 0.2 | 0.0 | 0.0 | 0.2 | 11 | 4 | 1 | 7 | 47 | 91 | 150 | 35 | 839 | 39,034 | 344 | 4.0 | 3,574 |
| Unknown Therapeutic Category | 0.4 | 0.0 | 0.0 | 0.0 | 7 | 0 | 0 | 0 | 16 | 0 | 0 | 0 | 2,107 | 34,223 | 460 | 5.4 | 5,109 |
| TOTAL NO. OF RX AND RX \$ | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | 583,987 | 27,897,150 | n.a. | n.a. | n.a. |

a. Table D.9 includes the beneficiaries represented by Cell H of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2004. A total of 7,370 beneficiaries who were in nursing facilities for part of their enrollment and their 69,047 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2004. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. For information about these therapeutic categories, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

e. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. For information about this classification method, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

In Washington, 0.3 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined.

Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE D.10

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS,
BY TOP-10 DRUG GROUP^{a, b, c, d}

DUAL ELIGIBLE BENEFICIARIES, WASHINGTON, 2004

| | | | Users | | | Among Users | | |
|------------------------------------------|----------------------|-----------|-----------------------------|----------------|------------------|-------------|-------------------|--|
| | | | As a Percentage of All-Year | _ | | | | |
| | | Number of | Nursing Facility | Number of | Number of Rx per | | Rx \$ per Benefit | |
| Top 10 Drug Groups in Nursing Facilities | Total Medicaid Rx \$ | Users | Residents | Benefit Months | Benefit Month | \$ per Rx | Month | |
| ANTIPSYCHOTICS | \$4,535,513 | 3,507 | 41.1 % | 37,761 | 0.8 | \$150 | \$120 | |
| ANTIDEPRESSANTS | 3,108,590 | 6,469 | 75.8 | 68,927 | 0.9 | 52 | 45 | |
| ANTICONVULSANT | 2,000,829 | 2,641 | 31.0 | 28,848 | 1.0 | 71 | 69 | |
| ULCER DRUGS | 1,855,735 | 4,264 | 50.0 | 45,404 | 0.8 | 52 | 41 | |
| MISC PSYCHOTHERAPEUTIC AND | | | | | | | | |
| NEUROLOGICAL | 1,692,741 | 1,300 | 15.2 | 13,702 | 0.8 | 159 | 124 | |
| ANALGESICS - Narcotic | 1,493,766 | 5,143 | 60.3 | 52,506 | 0.8 | 34 | 28 | |
| ANTIDIABETIC | 1,096,497 | 2,909 | 34.1 | 30,702 | 0.9 | 38 | 36 | |
| ANTIHYPERLIPIDEMIC | 860,042 | 1,492 | 17.5 | 15,820 | 0.8 | 66 | 54 | |
| MISC. ENDOCRINE | 837,399 | 1,567 | 18.4 | 17,087 | 0.7 | 70 | 49 | |
| ANTIASTHMATIC | 807,580 | 2,710 | 31.8 | 29,028 | 0.4 | 64 | 28 | |
| Total | 18,288,692 | 32,002 | | 339,785 | n.a. | n.a. | n.a. | |

Source: Data for this table are from the MAX 2004 file for Washington, released by CMS in 00/2007. This table was produced on 04/10/2008.

Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table D.10 includes the beneficiaries represented by Cell H of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2004. A total of 7,370 beneficiaries who were in nursing facilities for part of their enrollment and their 69,047 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2004 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

TABLE D.10A

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR TOP 10 DRUG GROUPS COMBINED AND FIRST

AND SECOND TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c, d}

DUAL ELIGIBLE BENEFICIARIES, WASHINGTON, 2004

| | All Top 10 Dr | ug Groups | | ANTIPS | SYCHOTICS | | | | ANTIDE | PRESSANTS | | |
|---------------------------------|---------------|--------------|--------------------|---------------------------------------------------|--------------------------------------------------|-------------------------|---------------|--------------------|---------------------------------------------------------------|--------------------------------------------------|-------------------------|---------------|
| Beneficiary Characteristics | Number of Rx | Rx\$ | Number of Users | Users as % of All-Year Nursing Facility Residents | Number of Benefit Months Among Users | Mean Number of Rx | Mean Rx \$ | Number of Users | Users as % of All-Year Nursing Facility Residents | Number of Benefit Months Among Users | Mean Number of Rx | Mean Rx \$ |
| All | 275,050 | \$18,288,692 | 3,507 | 41.1 % | 37,761 | 0.8 | \$120 | 6,469 | 75.8 % | 68,927 | 0.9 | \$45 |
| Female | 200,995 | 13,134,681 | 2,492 | 40.4 | 27,052 | 0.8 | 117 | 4,770 | 77.3 | 51,291 | 0.9 | 45 |
| Disabled | 18,485 | 1,575,506 | 191 | 48.1 | 2,205 | 0.9 | 160 | 370 | 93.2 | 4,163 | 0.9 | 50 |
| r | 18,296 | 1,567,617 | 189 | 48.0 | 2,185 | 0.9 | 161 | 368 | 93.4 | 4,139 | 0.9 | 50 |
| 64 or younge | 189 | 7,889 | 2 | 66.7 | 20 | 2.8 | 93 | 2 | 66.7 | 24 | 1.0 | 55 |
| 65-74 | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 75-84 | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 85 and older Other Eligibles | 182,510 | 11,559,175 | 2,301 | 39.8 | 24,847 | 0.8 | 113 | 4,400 | 76.2 | 47,128 | 0.9 | 44 |
| r | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 64 or younge | 26,264 | 1,964,890 | 303 | 51.4 | 3,376 | 0.9 | 145 | 507 | 86.1 | 5,525 | 0.9 | 49 |
| 65-74 | 69,679 | 4,404,019 | 875 | 45.1 | 9,535 | 0.8 | 117 | 1,555 | 80.2 | 16,635 | 0.9 | 44 |
| 75-84 | 86,567 | 5,190,266 | 1,123 | 34.6 | 11,936 | 0.7 | 100 | 2,338 | 72.0 | 24,968 | 0.9 | 43 |
| 85 and older Male | 74.055 | 5,154,011 | 1.015 | 43.0 | 10.709 | 0.8 | 129 | 1.699 | 72.1 | 17.636 | 0.9 | 47 |
| Disabled | 19,065 | 1,683,167 | 229 | 51.9 | 2,581 | 0.8 | 175 | 359 | 81.4 | 4.014 | 0.9 | 55 |
| Disabled | 18,855 | 1,669,460 | 226 | 52.0 | 2,552 | 0.8 | 175 | 356 | 81.8 | 3,980 | 0.9 | 55 |
| 64 or younge ' | 210 | 13,707 | 3 | 50.0 | 29 | 1.3 | 204 | 3 | 50.0 | 34 | 0.8 | 56 |
| 65-74 | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 75-84 | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 85 and older Other Eligibles | 54,990 | 3,470,844 | 786 | 41.0 | 8,128 | 0.8 | 114 | 1,340 | 69.9 | 13,622 | 0.9 | 45 |
| r | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 64 or younge | 14.715 | 998.493 | 172 | 44.8 | 1,909 | 0.9 | 155 | 286 | 74.5 | 3.106 | 0.9 | 49 |
| 65-74 | 24,177 | 1,503,950 | 348 | 41.9 | 3,579 | 0.8 | 106 | 603 | 72.6 | 6,131 | 0.9 | 45 |
| 75-84 | 16,098 | 968,401 | 266 | 37.9 | 2,640 | 0.8 | 97 | 451 | 64.2 | 4,385 | 0.9 | 41 |
| 85 and older Unknown | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table D.10A includes the beneficiaries represented by Cell H of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2004. A total of 7,370 beneficiaries who were in nursing facilities for part of their enrollment and their 69,047 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had feefor-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2004 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

TABLE D.10B

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY

AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c, d}

DUAL ELIGIBLE BENEFICIARIES, WASHINGTON, 2004

| | | ANTICO | ONVULSANT | | | | ULCE | R DRUGS | | | MISC PSYCHOTHERAPEUTIC AND NEUROLOGICAL | | | | |
|---------------------------------|--------------------|---------------------------------------------------------------|--------------------------------------------------|-------------------------|---------------|--------------------|---------------------------------------------------------------|--------------------------------------------------|-------------------------|---------------|-----------------------------------------|---------------------------------------------------------------|------------|------------|---------------|
| Beneficiary Characteristics | Number of Users | Users as % of All-Year Nursing Facility Residents | Number of Benefit Months Among Users | Mean Number of Rx | Mean Rx \$ | Number of Users | Users as % of All-Year Nursing Facility Residents | Number of Benefit Months Among Users | Mean Number of Rx | Mean Rx \$ | Number of Users | Users as % of All-Year Nursing Facility Residents | Users | of Rx | Mean Rx \$ |
| All | 2,641 | 31.0 % | 28,848 | 1.0 | \$69 | 4,264 | 50.0 % | 45,404 | 8.0 | \$41 | 1,300 | 15.2 % | 13,702 | 0.8 | \$124 |
| Female | 1,787 | 28.9 | 19,580 | 1.0 | 63 | 3,059 | 49.5 | 32,745 | 0.8 | 40 | 936 | 15.2 | 10,119 | 0.8 | 126 |
| Disabled | 268 | 67.5 | 3,089 | 1.1 | 88 | 205 | 51.6 | 2,276 | 8.0 | 48 | 41 | 10.3 | 483 | 0.8 | 536 |
| r 64 or younge | 265 | 67.3 | 3,061 | 1.1 | 88 | 205 | 52.0 | 2,276 | 0.8 | 48 | 40 | 10.2 | 475 | 0.8 | 545 |
| 65-74 | 3 | 100.0 | 28 | 1.8 | 88 | 0 | 0.0 | 0 | 0.0 | 0 | 1 | 33.3 | 8 | 0.4 | 30 |
| 75-84 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 85 and older | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| Other Eligibles | 1,519 | 26.3 | 16,491 | 0.9 | 59 | 2,854 | 49.4 | 30,469 | 0.8 | 39 | 895 | 15.5 | 9,636 | 0.8 | 106 |
| 64 or younge | 0 311 | 0.0 52.8 | 0 3,419 | 0.0 1.0 | 0 80 | 0 326 | 0.0 55.3 | 0 3,549 | 0.0 0.8 | 0 43 | 0 | 0.0 10.4 | 0 688 | 0.0 0.9 | 0 245 |
| 65-74 | 636 | 32.8 | 6,924 | 0.9 | 58 | 997 | 55.3 51.4 | 10,570 | 0.8 | 43 40 | 61 375 | 19.3 | 4,000 | 0.9 | 103 |
| 75-84 | 572 | 32.6 17.6 | 6,148 | 0.9 | 48 | 1,531 | 47.1 | 16,350 | 0.8 | 38 | 459 | 19.3 | 4,000 | 0.8 | 89 |
| 85 and older | 312 | | • | 0.5 | _ | 1,001 | 77.1 | 10,550 | | | 400 | 14.1 | 4,540 | | |
| Male | 854 | 36.2 | 9,268 | 1.0 | 82 | 1,205 | 51.1 | 12,659 | 8.0 | 44 | 364 | 15.4 | 3,583 | 8.0 | 116 |
| Disabled | 328 | 74.4 | 3,657 | 1.2 | 117 | 260 | 59.0 | 2,897 | 0.8 | 56 | 18 | 4.1 | 201 | 0.8 | 518 |
| r 64 or younge | 326 | 74.9 | 3,635 | 1.2 | 118 | 256 | 58.9 | 2,859 | 0.8 | 56 | 18 | 4.1 | 201 | 0.8 | 518 |
| 65-74 | 2 | 33.3 | 22 | 1.1 | 66 | 4 | 66.7 | 38 | 8.0 | 45 | 0 | 0.0 | 0 | 0.0 | 0 |
| 75-84 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 85 and older Other Eligibles | 0 | 0.0 27.4 | 0 | 0.0 | 0 | 0 | 0.0 | 0.700 | 0.0 | 0 | 0 346 | 0.0 | 0 | 0.0 | 0 |
| Other Eligibles | 526 0 | 0.0 | 5,611 0 | 0.9 0.0 | 60 0 | 945 0 | 49.3 0.0 | 9,762 0 | 0.8 | 40 0 | 0 | 18.0 0.0 | 3,382 0 | 0.8 | 92 0 |
| 64 or younge | 170 | 44.3 | 1,869 | 1.0 | 71 | 213 | 55.5 | 2,290 | 0.0 | 46 | 47 | 12.2 | 496 | 0.0 | 88 |
| 65-74 | 230 | 44.3 27.7 | 2.452 | 1.0 | 56 | 426 | 55.5 51.3 | 4,426 | 0.8 | 37 | 47 178 | 21.4 | 1,713 | 0.7 | 94 |
| 75-84 | 126 | 17.9 | 1,290 | 0.9 | 49 | 306 | 43.6 | 3,046 | 0.8 | 41 | 121 | 17.2 | 1,173 | 0.8 | 90 |
| 85 and older | 120 | 17.5 | 1,250 | 0.5 | 73 | 300 | 40.0 | 3,040 | | 71 | 121 | | 1,175 | 0.0 | 30 |
| Unknown | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table D.10B includes the beneficiaries represented by Cell H of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2004. A total of 7,370 beneficiaries who were in nursing facilities for part of their enrollment and their 69,047 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2004 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

TABLE D.10C

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c, d} DUAL ELIGIBLE BENEFICIARIES, WASHINGTON, 2004

| | ANALGESICS - Narcotic | | | | | ANTI | DIABETIC | | | ANTIHYPERLIPIDEMIC | | | | | |
|----------------------------------------|-----------------------------|----------------------------------------------------------|------------------------------------------------------------|-------------------------|---------------|-----------------------|----------------------------------------------------------|------------------------------------------------------------|-------------------------|--------------------|-----------------------------|---------------------------------------------------|--------------------------------------------------|-------------------------|-----------------------|
| Beneficiary Characteristics | Number of Users 5,143 | Users as % of All-Year Nursing Facility Residents 60.3 % | Number of Benefit Months Among Users 52,506 | Mean Number of Rx | Mean Rx \$ | Number of Users 2,909 | Users as % of All-Year Nursing Facility Residents 34.1 % | Number of Benefit Months Among Users 30,702 | Mean Number of Rx | Mean Rx \$ | Number of Users 1,492 | Users as % of All-Year Nursing Facility Residents | Number of Benefit Months Among Users | Mean Number of Rx | Mean Rx \$ \$54 |
| | , | | • | | | • | | • | | · | , | | • | | |
| Female | 3,941 | 63.8 | 40,667 | 0.8 | 30 | 2,047 | 33.2 | 22,077 | 0.9 | 37 | 984 | 15.9 | 10,604 | 0.8 | 54 |
| Disabled | 254 | 64.0 | 2,829 | 1.1 | 38 | 156 | 39.3 | 1,750 | 1.2 | 61 | 97 | 24.4 | 1,113 | 8.0 | 57 57 |
| r 64 or younge | 254 | 64.5 | 2,829 | 1.1 | 38 | 152 | 38.6 | 1,706 | 1.2 | 61 | 97 | 24.6 | 1,113 | 8.0 | 57 |
| 65-74 | 0 | 0.0 | 0 | 0.0 | 0 | 4 | 133.3 | 44 | 1.1 | 40 | 0 | 0.0 | 0 | 0.0 | 0 |
| 75-84 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 227 | 0.0 | 0 | 0 | 0.0 | 0 404 | 0.0 | 0 |
| 85 and older Other Eligibles | 3,687 | 63.8 | 37,838 | 0.8 | 29 | 1,891 | 32.7 | 20,327 | 0.9 | 35 | 887 | 15.4 | 9,491 | 0.8 | 54 |
| r 64 or younge | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 43 | 0 | 0.0 | 0 | 0.0 | 0 |
| 65-74 | 398 | 67.6 | 4,146 | 1.1 | 41 | 321 | 54.5 | 3,581 | 0.9 | 43 34 | 169 | 28.7 | 1,864 | 0.8 | 60 |
| 75-84 | 1,283 | 66.2 | 13,253 | 0.8 | 29 | 828 | 42.7 | 8,845 | 0.9 | | 412 | 21.2 | 4,369 | 0.8 | 53 |
| 85 and older | 2,006 | 61.7 | 20,439 | 0.7 | 27 | 742 | 22.8 | 7,901 | 0.9 | 31 | 306 | 9.4 | 3,258 | 8.0 | 52 |
| Male | 1,202 | 51.0 | 11,839 | 0.8 | 23 | 862 | 36.6 | 8,625 | 0.9 | 33 | 508 | 21.5 | 5,216 | 0.8 | 55 |
| Disabled | 234 | 53.1 | 2,546 | 1.1 | 40 | 129 | 29.3 | 1,316 | 1.0 | 42 | 92 | 20.9 | 998 | 0.9 | 70 |
| r | 229 | 52.6 | 2,496 | 1.1 | 40 | 128 | 29.4 | 1,306 | 1.0 | 42 | 91 | 20.9 | 986 | 0.9 | 70 |
| 64 or younge | 5 | 83.3 | 50 | 1.2 | 10 | 1 | 16.7 | 10 | 1.4 | 84 | 1 | 16.7 | 12 | 0.8 | 59 |
| 65-74 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 75-84 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 85 and older Other Eligibles | 968 | 50.5 | 9,293 | 0.7 | 19 | 733 | 38.2 | 7,309 | 0.9 | 32 | 416 | 21.7 | 4,218 | 0.8 | 51 |
| r | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 64 or younge | 193 | 50.3 | 2,113 | 1.0 | 28 | 189 | 49.2 | 2,004 | 1.1 | 38 | 124 | 32.3 | 1,325 | 0.8 | 56 |
| 65-74 | 397 | 47.8 | 3,798 | 0.6 | 16 | 353 | 42.5 | 3,494 | 0.9 | 31 | 197 | 23.7 | 1,948 | 0.8 | 47 |
| 75-84 | 378 | 53.8 | 3,382 | 0.6 | 17 | 191 | 27.2 | 1,811 | 8.0 | 26 | 95 | 13.5 | 945 | 0.9 | 53 |
| 85 and older Unknown | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |

Source: Data for this table are from the MAX 2004 file for Washington, released by CMS in 00/2007. This table was produced on 04/10/2008.

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit: \$ = Medicaid reimbursement.

a. Table D.10C includes the beneficiaries represented by Cell H of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2004. A total of 7,370 beneficiaries who were in nursing facilities for part of their enrollment and their 69,047 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2004 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

TABLE D.10D

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR NINTH AND TENTH TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c, d} DUAL ELIGIBLE BENEFICIARIES, WASHINGTON, 2004

| | MISC. ENDOCRINE | | | | | ANTIA | STHMATIC | | | | Benefit | |
|---------------------------------|-----------------|-----------------------------------------|-----------------------------------------|-------|------|-----------|-----------------------------------------|-----------------------------------------|-------|-------|---------------------------------|-----------------------------------------|
| Beneficiary | Number of | Users as % of All-Year Nursing Facility | Number of Benefit Months Among | | Mean | Number of | Users as % of All-Year Nursing Facility | Number of Benefit Months Among | | Mean | All-Year Nursing Facility | Months Among All- Year Nursing Facility |
| Characteristics | Users | Residents | Users | of Rx | Rx\$ | Users | Residents | Users | of Rx | Rx \$ | Residents | Residents |
| All | 1,567 | 18.4 % | 17,087 | 0.7 | \$49 | 2,710 | 31.8 % | 29,028 | 0.4 | \$28 | 8,532 | 87,225 |
| Female | 1,375 | 22.3 | 15,075 | 0.7 | 50 | 1,887 | 30.6 | 20,598 | 0.4 | 26 | 6,174 | 63,910 |
| Disabled | 68 | 17.1 | 781 | 0.6 | 55 | 133 | 33.5 | 1,500 | 0.5 | 35 | 397 | 4,472 |
| r | 67 | 17.0 | 773 | 0.6 | 55 | 132 | 33.5 | 1,492 | 0.5 | 35 | 394 | 4,440 |
| 64 or younge | 1 | 33.3 | 8 | 0.8 | 31 | 1 | 33.3 | 8 | 0.1 | 2 | 3 | 32 |
| 65-74 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0 |
| 75-84 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0 |
| 85 and older Other Eligibles | 1,307 | 22.6 | 14,294 | 0.7 | 49 | 1,754 | 30.4 | 19,098 | 0.4 | 25 | 5,777 | 59,438 |
| r 64 or younge | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0 |
| 64 or younge 65-74 | 118 | 20.0 | 1,260 | 8.0 | 61 | 251 | 42.6 | 2,692 | 0.5 | 36 | 589 | 6,200 |
| 75-84 | 424 | 21.9 | 4,598 | 0.7 | 49 | 610 | 31.5 | 6,642 | 0.4 | 27 | 1,939 | 19,999 |
| 85 and older | 765 | 23.5 | 8,436 | 0.7 | 47 | 893 | 27.5 | 9,764 | 0.4 | 21 | 3,249 | 33,239 |
| Male | 192 | 8.1 | 2,012 | 0.7 | 46 | 823 | 34.9 | 8,430 | 0.5 | 32 | 2,358 | 23,315 |
| Disabled | 50 | 11.3 | 565 | 0.6 | 46 | 134 | 30.4 | 1,489 | 0.6 | 44 | 441 | 4,740 |
| r | 50 | 11.5 | 565 | 0.6 | 46 | 132 | 30.3 | 1,465 | 0.6 | 44 | 435 | 4,685 |
| 64 or younge | 0 | 0.0 | 0 | 0.0 | 0 | 2 | 33.3 | 24 | 0.4 | 29 | 6 | 55 |
| 65-74 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0 |
| 75-84 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0 |
| 85 and older Other Eligibles | 142 | 7.4 | 1,447 | 0.7 | 45 | 689 | 35.9 | 6,941 | 0.5 | 30 | 1,917 | 18,575 |
| r | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0 |
| 64 or younge | 19 | 4.9 | 218 | 0.7 | 48 | 146 | 38.0 | 1,535 | 0.5 | 32 | 384 | 3,963 |
| 65-74 | 70 | 8.4 | 673 | 0.6 | 42 | 313 | 37.7 | 3,164 | 0.5 | 31 | 831 | 8,064 |
| 75-84 | 53 | 7.5 | 556 | 0.8 | 49 | 230 | 32.8 | 2,242 | 0.4 | 27 | 702 | 6,548 |
| 85 and older | | | | | | | | • | | | | |
| Unknown | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0 |

Source: Data for this table are from the MAX 2004 file for Washington, released by CMS in 00/2007. This table was produced on 04/10/2008.

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table D.10D includes the beneficiaries represented by Cell H of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2004. A total of 7,370 beneficiaries who were in nursing facilities for part of their enrollment and their 69,047 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2004 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

TABLE D.11

USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D

AMONG DUALS, BY BENEFICIARY CHARACTERISTIC^{a,b}

WASHINGTON, 2004

| | Number of | Percentage of | | | | | | Part D Excluded | |
|-----------------------------------|------------------------------------|--------------------|-----------------|----------|--------------------------------|--------------|------------------------------|-------------------|----------------------------------|
| Danafiaian | Beneficiaries with | Beneficiaries with | | | Part D | Tatal Dart D | Ф Dot D | Rx \$ as a | Tatal Niverban |
| Beneficiary Characteristics | at Least One Part D Excluded Rx | at Least One Part | per Beneficiary | Part D | Excluded Rx \$ per Beneficiary | Total Part D | \$ per Part D Excluded Rx | Percentage of All | Total Number of Beneficiaries |
| All | 66,949 | 65.9 % | 9.0 | 911,106 | \$99 | \$10,097,856 | \$11 | 3.4 % | 101,583 |
| All | 00,949 | 03.9 / | 9.0 | 911,100 | фээ | \$10,097,030 | фіі | 3.4 /6 | 101,363 |
| Age | | | | | | | | | |
| 5 and younger | 9 | 100.0 | 24.1 | 217 | 565 | 5,085 | 23 | 6.5 | 9 |
| 6-14 | 17 | 85.0 | 18.5 | 370 | 336 | 6,716 | 18 | 3.8 | 20 |
| 15-20 | 67 | 38.5 | 3.2 | 563 | 56 | 9,720 | 17 | 2.5 | 174 |
| 21-44 | 10,444 | 53.3 | 5.3 | 104,435 | 69 | 1,353,531 | 13 | 2.2 | 19,596 |
| 45-64 | 16,498 | 67.2 | 9.5 | 233,258 | 119 | 2,913,918 | 12 | 3.0 | 24,566 |
| 65-74 | 14,560 | 68.4 | 9.7 | 207,071 | 103 | 2,190,390 | 11 | 4.0 | 21,283 |
| 75-84 | 14,309 | 70.5 | 10.3 | 208,659 | 103 | 2,082,488 | 10 | 4.2 | 20,283 |
| 85 and older | 11,045 | 70.6 | 10.0 | 156,533 | 98 | 1,536,008 | 10 | 4.8 | 15,652 |
| Unknown | 0 | 0.0 | 0.0 | 0 | 0 | 0 | 0 | 0.0 | 0 |
| Basis of Eligibility ^c | | | | | | | | | |
| Aged | 39,851 | 69.8 | 10.0 | 571,622 | 102 | 5,801,576 | 10 | 4.3 | 57,080 |
| Disabled | 26,793 | 61.3 | 7.7 | 337,715 | 98 | 4,274,745 | 13 | 2.7 | 43,706 |
| Adults | 291 | 37.4 | 2.1 | 1,604 | 25 | 19,512 | 12 | 2.2 | 779 |
| Children | 14 | 77.8 | 9.2 | 165 | 112 | 2,023 | 12 | 3.4 | 18 |
| Unknown | 0 | 0.0 | 0.0 | 0 | 0 | 0 | 0 | 0.0 | 0 |
| Gender | | | | | | | | | |
| Female | 44,731 | 70.6 | 10.1 | 637,830 | 110 | 6,954,165 | 11 | 3.7 | 63,373 |
| Male | 22,218 | 58.1 | 7.2 | 273,276 | 82 | 3,143,691 | 12 | 3.0 | 38,210 |
| Unknown | 0 | 0.0 | 0.0 | 0 | 0 | 0 | 0 | 0.0 | 0 |
| | v | 0.0 | 0.0 | · · | · · | · · | · · | 0.0 | v |
| Race | 50.070 | 05.0 | 0.0 | 007.400 | 400 | 7.050.004 | 4.4 | 2.2 | 77.005 |
| White | 50,679 | 65.3 | 9.0 | 697,196 | 102 | 7,953,034 | 11 | 3.3 | 77,625 |
| African American | 3,073 | 64.4 | 8.1 | 38,472 | 91 | 436,611 | 11 | 3.4 | 4,772 |
| Other/unknown | 13,197 | 68.8 | 9.1 | 175,438 | 89 | 1,708,211 | 10 | 4.2 | 19,186 |
| Use of Nursing | | | | | | | | | |
| Facilities ^d | | | | | | | | | |
| Entire year | 5,232 | 61.3 | 5.9 | 50,213 | 96 | 815,892 | 16 | 2.9 | 8,532 |
| Part year | 5,679 | 77.1 | 9.2 | 67,605 | 115 | 848,134 | 13 | 3.8 | 7,370 |
| None | 56,038 | 65.4 | 9.3 | 793,288 | 98 | 8,433,830 | 11 | 3.5 | 85,681 |
| Maintenance | | | | | | | | | |
| Assistance Status | | | | | | | | | |
| Cash | 32,361 | 63.4 | 7.7 | 394,967 | 84 | 4,315,309 | 11 | 3.1 | 51,079 |
| Medically needy | 1,511 | 67.2 | 7.1 | 16,031 | 92 | 207,178 | 13 | 2.3 | 2,250 |
| Poverty related | 906 | 27.2 | 1.8 | 5,973 | 23 | 78,104 | 13 | 2.9 | 3,326 |
| Other/unknown | 32,171 | 71.6 | 11.0 | 494,135 | 122 | 5,497,265 | 11 | 3.8 | 44,928 |
| | • | | | Table D4 | 1 | | | Dual Elia | |

Table D11

Dual Eligible Beneficiaries

- a. Table D.11 includes the beneficiaries represented by Cell G of Table 1. Beneficiaries include all dual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2004.
- b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.
- c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE D.12

USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D

AMONG DUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC^{a,b}

WASHINGTON, 2004

| Beneficiary | Number Rx per | Rx \$ per Benefit | | Barbiturate \$ per Be | | Number of Benefit |
|-----------------------------------|---------------|-------------------|-----------|-----------------------|---------------|-------------------|
| Characteristics | Benefit Month | Month | \$ per Rx | Benefit Month | Benefit Month | Months |
| All | 0.8 | \$9 | \$11 | \$0 | \$2 | 1,079,506 |
| Age | | | | | | |
| 5 and younger | 2.2 | 51 | 23 | 0 | 2 | 100 |
| 6-14 | 1.8 | 32 | 18 | 0 | 2 | 209 |
| 15-20 | 0.3 | 5 | 17 | 0 | 0 | 1,927 |
| 21-44 | 0.5 | 6 | 13 | 0 | 2 | 213,906 |
| 45-64 | 0.9 | 11 | 12 | 0 | 3 | 268,227 |
| 65-74 | 0.9 | 10 | 11 | 0 | 1 | 229,970 |
| 75-84 | 1.0 | 10 | 10 | 0 | 1 | 211,858 |
| 85 and older | 1.0 | 10 | 10 | 0 | 1 | 153,309 |
| Unknown | 0.0 | 0 | 0 | 0 | 0 | 0 |
| Basis of Eligibility ^c | | | | | | |
| Aged | 1.0 | 10 | 10 | 0 | 1 | 594,141 |
| Disabled | 0.7 | 9 | 13 | 0 | 2 | 479,450 |
| Adults | 0.3 | 3 | 12 | 0 | 1 | 5,730 |
| Children | 0.9 | 11 | 12 | 0 | 1 | 185 |
| Unknown | 0.0 | 0 | 0 | 0 | 0 | 0 |
| Gender | | | | | | |
| Female | 0.9 | 10 | 11 | 0 | 2 | 674,881 |
| Male | 0.7 | 8 | 12 | 0 | 1 | 404,625 |
| Unknown | 0.0 | 0 | 0 | 0 | 0 | 0 |
| Race | | | | | | |
| White | 0.8 | 10 | 11 | 0 | 2 | 821,164 |
| African American | 0.8 | 9 | 11 | 0 | 1 | 50,806 |
| Other/unknown | 0.8 | 8 | 10 | 0 | 1 | 207,536 |
| Use of Nursing | | | | | | |
| Facilities ^d | | | | | | |
| Entire year | 0.6 | 9 | 16 | 0 | 2 | 87,225 |
| Part year | 1.0 | 12 | 13 | 0 | 2 | 69,047 |
| None | 0.9 | 9 | 11 | 0 | 2 | 923,234 |
| Maintenance | | | | | | |
| Assistance Status | | | | | | |
| Cash | 0.7 | 8 | 11 | 0 | 1 | 566,336 |
| Medically needy | 0.7 | 9 | 13 | 0 | 2 | 23,469 |
| Poverty related | 0.2 | 3 | 13 | 0 | 1 | 28,477 |
| Other/unknown | 1.1 | 12 | 11 | 0 | 2 | 461,224 |

- a. Table D.12 includes the beneficiaries represented by Cell G of Table 1. Beneficiaries include all dual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2004.
- b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.
- c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE D.13

USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG DUALS^{a,b,c} WASHINGTON, 2004

| | | | | Rx \$ as a Percentage of All Part D | | ı | Number Rx as a Percentage of All Part D |
|------------------------------|-----------------|----------------|--------------|-------------------------------------------|------------------|-----------|-----------------------------------------------|
| Drug Category | Number of Users | Rx \$ per User | Total Rx \$ | Excluded Rx \$ | Total Number Rx. | \$ per Rx | Excluded Rx |
| All | 108,832 | \$93 | \$10,097,856 | 100.0 % | 911,106 | \$11 | 100.0 % |
| Anorexia or weight loss/gain | 0 | 0 | 0 | 0.0 | 0 | 0 | 0.0 |
| Fertility drugs | 0 | 0 | 0 | 0.0 | 0 | 0 | 0.0 |
| Drugs for cosmetic purposes | 65 | 22 | 1,418 | 0.0 | 134 | 11 | 0.0 |
| Cough and cold medications | 11,123 | 46 | 513,601 | 5.1 | 29,466 | 17 | 3.2 |
| Vitamins and minerals | 18,376 | 125 | 2,295,332 | 22.7 | 130,840 | 18 | 14.4 |
| Non-prescription drugs | 52,564 | 96 | 5,029,556 | 49.8 | 579,256 | 9 | 63.6 |
| Barbiturates | 715 | 77 | 54,725 | 0.5 | 7,394 | 7 | 0.8 |
| Benzodiazepines | 22,988 | 81 | 1,871,632 | 18.5 | 152,632 | 12 | 16.8 |
| Other Part D Excl Rx Drugs | 3,001 | 110 | 331,592 | 3.3 | 11,384 | 29 | 1.2 |

Source: Data for this table are from the MAX 2004 file for Washington, released by CMS in 00/2007. This table was produced on 04/10/2008.

- b. Includes OTC drugs as well as prescription drugs.
- c. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table D.13 includes the beneficiaries represented by Cell G of Table 1. Beneficiaries include all dual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2004. A user is a beneficiary who had at least one prescription filled for a Part D excluded drug in 2004. A beneficiary who used drugs from two or more Part D excluded categories was counted as a user for each category. Therefore, the sum of users across drug categories may exceed the total number of individual users as noted on Table D11.

SUPPLEMENTAL TABLE 1 MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES^{a, b} WASHINGTON, 2004

Total Number of Dual Eligible Beneficiaries

Total Pharmacy Reimbursement for Dual Eligible Beneficiaries

Mean Pharmacy Reimbursement per Dual Eligible Beneficiary

101,583 \$294,229,288 \$2,896

| Annual Pharmacy Reimbursement per | | | | Percent of Total Pharmacy |
|-----------------------------------|-------------------------|-------------------------------|------------------------|---------------------------|
| Beneficiary | Number of Beneficiaries | Percent of Dual Beneficiaries | Pharmacy Reimbursement | Reimbursement |
| \$0 | 10,705 | 10.5 % | \$0 | 0.0 % |
| 1-500 | 18,123 | 17.8 | 3,726,997 | 1.3 |
| 501-1,000 | 10,693 | 10.5 | 7,936,233 | 2.7 |
| 1,001-1,500 | 8,838 | 8.7 | 11,000,328 | 3.7 |
| 1,501-2,000 | 7,515 | 7.4 | 13,102,104 | 4.5 |
| 2,001-2,500 | 6,536 | 6.4 | 14,687,337 | 5.0 |
| 2,501-3,000 | 5,510 | 5.4 | 15,126,718 | 5.1 |
| 3,001-3,500 | 4,742 | 4.7 | 15,392,916 | 5.2 |
| 3,501-4,000 | 4,132 | 4.1 | 15,475,983 | 5.3 |
| 4,001-4,500 | 3,533 | 3.5 | 14,991,354 | 5.1 |
| 4,501-5,000 | 2,977 | 2.9 | 14,118,532 | 4.8 |
| 5,001-5,500 | 2,468 | 2.4 | 12,937,536 | 4.4 |
| 5,501-6,000 | 2,146 | 2.1 | 12,327,122 | 4.2 |
| 6,001-6,500 | 1,819 | 1.8 | 11,355,064 | 3.9 |
| 6,501-7,000 | 1,520 | 1.5 | 10,240,468 | 3.5 |
| 7,001-7,500 | 1,295 | 1.3 | 9,380,932 | 3.2 |
| 7,501-8,000 | 1,080 | 1.1 | 8,360,866 | 2.8 |
| 8,001-8,500 | 970 | 1.0 | 7,999,688 | 2.7 |
| 8,501-9,000 | 770 | 0.8 | 6,738,779 | 2.3 |
| 9,001-9,500 | 695 | 0.7 | 6,419,441 | 2.2 |
| 9,501-10,000 | 633 | 0.6 | 6,160,350 | 2.1 |
| 10,001+ | 4,883 | 4.8 | 76,750,540 | 26.1 |

Source: Data for this table are from the MAX 2004 file for Washington, released by CMS in 00/2007. This table was produced on 04/10/2008.

Supp Table 1 10/16/2008

a. This table is based on prescription drug claims for beneficiaries who had Medicare as well as Medicaid fee-for-service pharmacy benefit coverage during some or all months of Medicaid enrollment in 2004.

b. Medicaid reimbursement amounts in this table do not reflect federally required rebates from drug manufacturers to states.

SUPPLEMENTAL TABLE 1A MEDICAID PHARMACY REIMBURSEMENT FOR DISABLED DUAL ELIGIBLE BENEFICIARIES UNDER AGE $65^{a, b, c}$ WASHINGTON, 2004

Total Number of Disabled Dual Eligible Beneficiaries, Age < 65

Total Pharmacy Reimbursement for Disabled Dual Eligible Beneficiaries, Age < 65

Mean Pharmacy Reimbursement per Disabled Dual Eligible Beneficiary, Age < 65

43,556 \$156,957,586 \$3,604

| Annual Pharmacy Reimbursement | Percent of I | Disabled Dual Beneficiaries, | | Percent of Total Pharmacy |
|-------------------------------|-------------------------|------------------------------|------------------------|---------------------------|
| per Beneficiary | Number of Beneficiaries | Age < 65 | Pharmacy Reimbursement | Reimbursement |
| \$0 | 5,400 | 12.4 % | 0 | 0.0 % |
| 1-500 | 8,028 | 18.4 | 1,511,871 | 1.0 |
| 501-1,000 | 3,793 | 8.7 | 2,794,142 | 1.8 |
| 1,001-1,500 | 2,974 | 6.8 | 3,697,554 | 2.4 |
| 1,501-2,000 | 2,528 | 5.8 | 4,408,702 | 2.8 |
| 2,001-2,500 | 2,216 | 5.1 | 4,985,249 | 3.2 |
| 2,501-3,000 | 1,912 | 4.4 | 5,258,025 | 3.3 |
| 3,001-3,500 | 1,669 | 3.8 | 5,428,099 | 3.5 |
| 3,501-4,000 | 1,540 | 3.5 | 5,770,054 | 3.7 |
| 4,001-4,500 | 1,377 | 3.2 | 5,851,588 | 3.7 |
| 4,501-5,000 | 1,217 | 2.8 | 5,769,942 | 3.7 |
| 5,001-5,500 | 1,092 | 2.5 | 5,729,494 | 3.7 |
| 5,501-6,000 | 1,034 | 2.4 | 5,939,296 | 3.8 |
| 6,001-6,500 | 916 | 2.1 | 5,716,664 | 3.6 |
| 6,501-7,000 | 767 | 1.8 | 5,170,350 | 3.3 |
| 7,001-7,500 | 738 | 1.7 | 5,349,315 | 3.4 |
| 7,501-8,000 | 623 | 1.4 | 4,823,485 | 3.1 |
| 8,001-8,500 | 565 | 1.3 | 4,659,744 | 3.0 |
| 8,501-9,000 | 481 | 1.1 | 4,208,385 | 2.7 |
| 9,001-9,500 | 441 | 1.0 | 4,073,354 | 2.6 |
| 9,501-10,000 | 422 | 1.0 | 4,108,647 | 2.6 |
| 10,001+ | 3,823 | 8.8 | 61,703,626 | 39.3 |

a. This table is based on prescription drug claims for beneficiaries who had Medicare as well as Medicaid fee-for-service pharmacy benefit coverage during some or all months of Medicaid enrollment in 2004.

b. Medicaid reimbursement amounts in this table do not reflect federally required rebates from drug manufacturers to states.

c. This table is limited to dual eligible beneficiaries who were under age 65 and also indicated as disabled in the MAX files. Therefore, dual eligible beneficiaries under age 65 in "adults" or "children" basis-of-eligibility categories in Table D.2 are excluded because they were not classified as disabled in the MAX files. Disabled dual eligible beneficiaries age 65 and older are included in Supplemental Tables 1B through 1E, depending on their age.

SUPPLEMENTAL TABLE 1B MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 AND OLDER^{a, b} WASHINGTON, 2004

Total Number of Dual Eligible Beneficiaries, Age 65+
Total Pharmacy Reimbursement for Dual Eligible Beneficiaries, Age 65+
Mean Pharmacy Reimbursement per Dual Eligible Beneficiary, Age 65+

57,218 \$136,305,204 \$2,382

| Annual Pharmacy Reimbursement | | | | Percent of Total Pharmacy |
|-------------------------------|-------------------------|----------------------------------------|------------------------|---------------------------|
| per Beneficiary | Number of Beneficiaries | Percent of Dual Beneficiaries, Age 65+ | Pharmacy Reimbursement | Reimbursement |
| \$0 | 5,051 | 8.8 % | 0 | 0.0 % |
| 1-500 | 9,831 | 17.2 | 2,169,552 | 1.6 |
| 501-1,000 | 6,822 | 11.9 | 5,085,532 | 3.7 |
| 1,001-1,500 | 5,809 | 10.2 | 7,234,472 | 5.3 |
| 1,501-2,000 | 4,952 | 8.7 | 8,634,332 | 6.3 |
| 2,001-2,500 | 4,301 | 7.5 | 9,661,044 | 7.1 |
| 2,501-3,000 | 3,582 | 6.3 | 9,823,961 | 7.2 |
| 3,001-3,500 | 3,062 | 5.4 | 9,929,030 | 7.3 |
| 3,501-4,000 | 2,577 | 4.5 | 9,650,024 | 7.1 |
| 4,001-4,500 | 2,146 | 3.8 | 9,097,353 | 6.7 |
| 4,501-5,000 | 1,754 | 3.1 | 8,320,284 | 6.1 |
| 5,001-5,500 | 1,370 | 2.4 | 7,176,345 | 5.3 |
| 5,501-6,000 | 1,110 | 1.9 | 6,376,776 | 4.7 |
| 6,001-6,500 | 898 | 1.6 | 5,607,145 | 4.1 |
| 6,501-7,000 | 750 | 1.3 | 5,049,866 | 3.7 |
| 7,001-7,500 | 552 | 1.0 | 3,995,274 | 2.9 |
| 7,501-8,000 | 455 | 0.8 | 3,522,110 | 2.6 |
| 8,001-8,500 | 403 | 0.7 | 3,323,198 | 2.4 |
| 8,501-9,000 | 287 | 0.5 | 2,513,055 | 1.8 |
| 9,001-9,500 | 254 | 0.4 | 2,346,087 | 1.7 |
| 9,501-10,000 | 209 | 0.4 | 2,032,580 | 1.5 |
| 10,001+ | 1,043 | 1.8 | 14,757,184 | 10.8 |

a. This table is based on prescription drug claims for beneficiaries who had Medicare as well as Medicaid fee-for-service pharmacy benefit coverage during some or all months of Medicaid enrollment in 2004.

b. Medicaid reimbursement amounts in this table do not reflect federally required rebates from drug manufacturers to states.

SUPPLEMENTAL TABLE 1C MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 TO 74 $^{\rm a,\,b}$ WASHINGTON, 2004

Total Number of Dual Eligible Beneficiaries, Age 65-74
Total Pharmacy Reimbursement for Dual Eligible Beneficiaries, Age 65-74
Mean Pharmacy Reimbursement per Dual Eligible Beneficiary, Age 65-74

21,283 \$54,390,177 \$2,556

| Annual Pharmacy Reimbursement per | | | | Percent of Total Pharmacy |
|-----------------------------------|-------------------------|------------------------------------------|------------------------|---------------------------|
| Beneficiary | Number of Beneficiaries | Percent of Dual Beneficiaries, Age 65-74 | Pharmacy Reimbursement | Reimbursement |
| \$0 | 2,466 | 11.6 % | 0 | 0.0 % |
| 1-500 | 3,523 | 16.6 | 742,285 | 1.4 |
| 501-1,000 | 2,335 | 11.0 | 1,749,268 | 3.2 |
| 1,001-1,500 | 1,963 | 9.2 | 2,448,315 | 4.5 |
| 1,501-2,000 | 1,737 | 8.2 | 3,026,292 | 5.6 |
| 2,001-2,500 | 1,506 | 7.1 | 3,389,011 | 6.2 |
| 2,501-3,000 | 1,187 | 5.6 | 3,258,807 | 6.0 |
| 3,001-3,500 | 1,023 | 4.8 | 3,318,874 | 6.1 |
| 3,501-4,000 | 868 | 4.1 | 3,253,100 | 6.0 |
| 4,001-4,500 | 756 | 3.6 | 3,210,516 | 5.9 |
| 4,501-5,000 | 657 | 3.1 | 3,125,541 | 5.7 |
| 5,001-5,500 | 522 | 2.5 | 2,735,074 | 5.0 |
| 5,501-6,000 | 436 | 2.0 | 2,503,809 | 4.6 |
| 6,001-6,500 | 363 | 1.7 | 2,267,083 | 4.2 |
| 6,501-7,000 | 305 | 1.4 | 2,055,446 | 3.8 |
| 7,001-7,500 | 239 | 1.1 | 1,730,140 | 3.2 |
| 7,501-8,000 | 228 | 1.1 | 1,766,253 | 3.2 |
| 8,001-8,500 | 196 | 0.9 | 1,613,793 | 3.0 |
| 8,501-9,000 | 147 | 0.7 | 1,284,087 | 2.4 |
| 9,001-9,500 | 122 | 0.6 | 1,127,896 | 2.1 |
| 9,501-10,000 | 105 | 0.5 | 1,022,052 | 1.9 |
| 10,001+ | 599 | 2.8 | 8,762,535 | 16.1 |

a. This table is based on prescription drug claims for beneficiaries who had Medicare as well as Medicaid fee-for-service pharmacy benefit coverage during some or all months of Medicaid enrollment in 2004.

b. Medicaid reimbursement amounts in this table do not reflect federally required rebates from drug manufacturers to states.

SUPPLEMENTAL TABLE 1D MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 75 TO $84^{a,\,b}$ WASHINGTON, 2004

Total Number of Dual Eligible Beneficiaries, Age 75-84

Total Pharmacy Reimbursement for Dual Eligible Beneficiaries, Age 75-84

Mean Pharmacy Reimbursement per Dual Eligible Beneficiary, Age 75-84

20,283 \$49,776,983 \$2,454

| Annual Pharmacy Reimbursement per | | | | Percent of Total Pharmacy |
|-----------------------------------|-------------------------|------------------------------------------|------------------------|---------------------------|
| Beneficiary | Number of Beneficiaries | Percent of Dual Beneficiaries, Age 75-84 | Pharmacy Reimbursement | Reimbursement |
| \$0 | 1,693 | 8.3 % | 0 | 0.0 % |
| 1-500 | 3,213 | 15.8 | 716,800 | 1.4 |
| 501-1,000 | 2,323 | 11.5 | 1,734,455 | 3.5 |
| 1,001-1,500 | 1,979 | 9.8 | 2,464,200 | 5.0 |
| 1,501-2,000 | 1,730 | 8.5 | 3,021,016 | 6.1 |
| 2,001-2,500 | 1,546 | 7.6 | 3,475,991 | 7.0 |
| 2,501-3,000 | 1,397 | 6.9 | 3,832,876 | 7.7 |
| 3,001-3,500 | 1,189 | 5.9 | 3,857,256 | 7.7 |
| 3,501-4,000 | 1,019 | 5.0 | 3,815,771 | 7.7 |
| 4,001-4,500 | 828 | 4.1 | 3,508,885 | 7.0 |
| 4,501-5,000 | 666 | 3.3 | 3,158,773 | 6.3 |
| 5,001-5,500 | 534 | 2.6 | 2,796,035 | 5.6 |
| 5,501-6,000 | 445 | 2.2 | 2,556,949 | 5.1 |
| 6,001-6,500 | 353 | 1.7 | 2,205,206 | 4.4 |
| 6,501-7,000 | 278 | 1.4 | 1,870,583 | 3.8 |
| 7,001-7,500 | 204 | 1.0 | 1,474,881 | 3.0 |
| 7,501-8,000 | 162 | 0.8 | 1,252,264 | 2.5 |
| 8,001-8,500 | 134 | 0.7 | 1,108,330 | 2.2 |
| 8,501-9,000 | 93 | 0.5 | 817,203 | 1.6 |
| 9,001-9,500 | 88 | 0.4 | 811,750 | 1.6 |
| 9,501-10,000 | 77 | 0.4 | 748,305 | 1.5 |
| 10,001+ | 332 | 1.6 | 4,549,454 | 9.1 |

a. This table is based on prescription drug claims for beneficiaries who had Medicare as well as Medicaid fee-for-service pharmacy benefit coverage during some or all months of Medicaid enrollment in 2004.

b. Medicaid reimbursement amounts in this table do not reflect federally required rebates from drug manufacturers to states.

SUPPLEMENTAL TABLE 1E MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 85 AND OLDER^{a, b} WASHINGTON, 2004

Total Number of Dual Eligible Beneficiaries, Age 85+
Total Pharmacy Reimbursement for Dual Eligible Beneficiaries, Age 85+
Mean Pharmacy Reimbursement per Dual Eligible Beneficiary, Age 85+

15,652 \$32,138,044 \$2,053

| Annual Pharmacy Reimbursement per | | | | Percent of Total Pharmacy | |
|-----------------------------------|-------------------------|----------------------------------------|------------------------|---------------------------|--|
| Beneficiary | Number of Beneficiaries | Percent of Dual Beneficiaries, Age 85+ | Pharmacy Reimbursement | Reimbursement | |
| \$0 | 892 | 5.7 % | 0 | 0.0 % | |
| 1-500 | 3,095 | 19.8 | 710,467 | 2.2 | |
| 501-1,000 | 2,164 | 13.8 | 1,601,809 | 5.0 | |
| 1,001-1,500 | 1,867 | 11.9 | 2,321,957 | 7.2 | |
| 1,501-2,000 | 1,485 | 9.5 | 2,587,024 | 8.0 | |
| 2,001-2,500 | 1,249 | 8.0 | 2,796,042 | 8.7 | |
| 2,501-3,000 | 998 | 6.4 | 2,732,278 | 8.5 | |
| 3,001-3,500 | 850 | 5.4 | 2,752,900 | 8.6 | |
| 3,501-4,000 | 690 | 4.4 | 2,581,153 | 8.0 | |
| 4,001-4,500 | 562 | 3.6 | 2,377,952 | 7.4 | |
| 4,501-5,000 | 431 | 2.8 | 2,035,970 | 6.3 | |
| 5,001-5,500 | 314 | 2.0 | 1,645,236 | 5.1 | |
| 5,501-6,000 | 229 | 1.5 | 1,316,018 | 4.1 | |
| 6,001-6,500 | 182 | 1.2 | 1,134,856 | 3.5 | |
| 6,501-7,000 | 167 | 1.1 | 1,123,837 | 3.5 | |
| 7,001-7,500 | 109 | 0.7 | 790,253 | 2.5 | |
| 7,501-8,000 | 65 | 0.4 | 503,593 | 1.6 | |
| 8,001-8,500 | 73 | 0.5 | 601,075 | 1.9 | |
| 8,501-9,000 | 47 | 0.3 | 411,765 | 1.3 | |
| 9,001-9,500 | 44 | 0.3 | 406,441 | 1.3 | |
| 9,501-10,000 | 27 | 0.2 | 262,223 | 0.8 | |
| 10,001+ | 112 | 0.7 | 1,445,195 | 4.5 | |

a. This table is based on prescription drug claims for beneficiaries who had Medicare as well as Medicaid fee-for-service pharmacy benefit coverage during some or all months of Medicaid enrollment in 2004.

b. Medicaid reimbursement amounts in this table do not reflect federally required rebates from drug manufacturers to states.

APPENDIX TABLE A.3
CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY^{a, b}
DUAL ELIGIBLE BENEFICIARIES, WASHINGTON, 2004

| Beneficiary | | | Number of Ben | eficiaries | | | | N | lumber of Bene | efit Months | | |
|----------------------------------------|---------|--------|---------------|------------|----------|---------|-----------|---------|----------------|-------------|----------|---------|
| Characteristics | All | Aged | Disabled | Adults | Children | Unknown | All | Aged | Disabled | Adults | Children | Unknown |
| All | 102,039 | 57,224 | 43,730 | 1,066 | 19 | 0 | 1,087,285 | 596,048 | 481,184 | 9,845 | 208 | 0 |
| Age | | | | | | | | | | | | |
| 5 and younger | 9 | 0 | 7 | 0 | 2 | 0 | 108 | 0 | 84 | 0 | 24 | 0 |
| 6-14 | 20 | 0 | 14 | 0 | 6 | 0 | 227 | 0 | 168 | 0 | 59 | 0 |
| 15-20 | 176 | 0 | 161 | 5 | 10 | 0 | 1,964 | 0 | 1,810 | 40 | 114 | 0 |
| 21-44 | 19,802 | 3 | 19,003 | 795 | 1 | 0 | 217,935 | 25 | 210,477 | 7,422 | 11 | 0 |
| 45-64 | 24,667 | 24 | 24,395 | 248 | 0 | 0 | 269,969 | 195 | 267,552 | 2,222 | 0 | 0 |
| 65-74 | 21,328 | 21,163 | 148 | 17 | 0 | 0 | 230,588 | 229,362 | 1,075 | 151 | 0 | 0 |
| 75-84 | 20,344 | 20,341 | 2 | 1 | 0 | 0 | 212,665 | 212,637 | 18 | 10 | 0 | 0 |
| 85 and older | 15,693 | 15,693 | 0 | 0 | 0 | 0 | 153,829 | 153,829 | 0 | 0 | 0 | 0 |
| Unknown | 0 | 0 | 0 | 0 | 0 | 0 | | 0 | 0 | 0 | 0 | 0 |
| Gender | | | | | | | | | | | | |
| Female | 63,669 | 40,635 | 22,324 | 698 | 12 | 0 | 679,893 | 425,741 | 247,523 | 6,495 | 134 | 0 |
| Male | 38,370 | 16,589 | 21,406 | 368 | 7 | 0 | 0 407,392 | 170,307 | 233,661 | 3,350 | 74 | 0 |
| Unknown | 0 | 0 | 0 | 0 | 0 | 0 | | 0 | 0 | 0 | 0 | 0 |
| Race | | | | | | | | | | | | |
| White | 77,939 | 41,281 | 35,916 | 730 | 12 | 0 | 826,652 | 422,472 | 397,154 | 6,899 | 127 | 0 |
| African American | 4,849 | 1,814 | 2,941 | 92 | 2 | 0 | 0 51,955 | 19,528 | 31,520 | 883 | 24 | 0 |
| Other/unknown | 19,251 | 14,129 | 4,873 | 244 | 5 | 0 | 208,678 | 154,048 | 52,510 | 2,063 | 57 | 0 |
| Use of Nursing Facilities ^c | | | | | | | | | | | | |
| Entire year | 8,532 | 7,694 | 838 | 0 | 0 | 0 | 87,226 | 78,014 | 9,212 | 0 | 0 | 0 |
| Part year | 7,370 | 6,398 | 971 | 1 | 0 | 0 | 69,121 | 59,054 | 10,055 | 12 | 0 | 0 |
| None | 86,137 | 43,132 | 41,921 | 1,065 | 19 | 0 | 930,938 | 458,980 | 461,917 | 9,833 | 208 | 0 |
| Maintenance Assistance Status | | | | | | | | | | | | |
| Cash | 51,262 | 23,419 | 27,500 | 340 | 3 | 0 | 570,033 | 263,925 | 302,581 | 3,494 | 33 | 0 |
| Medically needy | 2,250 | 834 | 1,416 | 0 | 0 | 0 | 23,659 | 8,485 | 15,174 | 0 | 0 | 0 |
| Poverty related | 3,328 | 1,424 | 1,758 | 139 | 7 | 0 | 28,686 | 11,069 | 16,268 | 1,281 | 68 | 0 |
| Other/unknown | 45,199 | 31,547 | 13,056 | 587 | 9 | 0 | 464,907 | 312,569 | 147,161 | 5,070 | 107 | 0 |
| Dual Status ^d | | | | | | | | | | | | |
| Full dual, all year | 97,069 | 54,853 | 41,182 | 1,015 | 19 | 0 | 1,036,349 | 572,702 | 454,137 | 9,302 | 208 | 0 |
| Full dual, part year | 4,970 | 2,371 | 2,548 | 51 | 0 | 0 | 50,936 | 23,346 | 27,047 | 543 | 0 | 0 |
| Managed Care (MC) Status | | | | | | | | | | | | |
| Fee-for-service (FFS) all year | 101,044 | 57,015 | 43,426 | 588 | 15 | 0 | 1,076,725 | 593,770 | 477,814 | 4,978 | 163 | 0 |
| FFS part year, with Rx claims | 456 | 47 | 246 | 160 | 3 | 0 | 4,936 | 525 | 2,760 | 1,618 | 33 | 0 |
| FFS part year, no Rx claims | 83 | 18 | 34 | 31 | 0 | 0 | 750 | 190 | 332 | 228 | 0 | 0 |
| MC all year, with Rx claims | 116 | 1 | 8 | 107 | 0 | 0 | 1,315 | 12 | 88 | 1,215 | 0 | 0 |
| MC all year, no Rx claims | 340 | 143 | 16 | 180 | 1 | 0 | 3,559 | 1,551 | 190 | 1,806 | 12 | 0 |

- a. Table A.3 includes the beneficiaries represented by Cell F of Table 1. Benefit months are months during which beneficiaries had pharmacy benefit coverage.
- b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.
- c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.
- d. The "Full dual, all year" group contains beneficiaries who had Medicare as well as Medicaid pharmacy benefits during all months of Medicaid enrollment in 2004. The "Full dual, part year" group contains beneficiaries who had such benefits for some, but not all, months of their enrollment. Refer to footnote g of Table 1 for more information about how we determined dual eligibility status.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.

APPENDIX TABLE A.4 MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS^a DUAL ELIGIBLE BENEFICIARIES, WASHINGTON, 2004

| Beneficiary | Beneficiaries Benefit Months in Ce | | Included in Cell G | of Table 1 | Excluded from Cell G of Table 1 | | |
|--------------------------------------------|---------------------------------------|---------------------------|-------------------------------|---------------------------|---------------------------------|---------------------------|--|
| Characteristics | Number of Nu Beneficiaries | mber of Benefit Months | Number of Nu Beneficiaries | mber of Benefit Months | Number of Num Beneficiaries | nber of Benefit Months | |
| All | 102,039 | 1,087,285 | 101,583 | 1,079,506 | 0 | 7,779 | |
| Fee-for-service (FFS) all year | 101,044 | 1,076,725 | 101,044 | 1,076,725 | 0 | 0 | |
| FFS part year, with Rx claims | 456 | 4,936 | 456 | 2,445 | 0 | 2,491 | |
| FFS part year, with no Rx claims | 83 | 750 | 83 | 336 | 0 | 414 | |
| Managed care (MC) all year, with Rx claims | 116 | 1,315 | 0 | 0 | 0 | 1,315 | |
| MC all year, with no Rx claims | 340 | 3,559 | 0 | 0 | 0 | 3,559 | |

Source: Data for this table are from the MAX 2004 file for Washington, released by CMS in 00/2007. This table was produced on 04/10/2008.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare and Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.

a. Benefit months are months during which beneficiaries had pharmacy benefit coverage.